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2 | SUMMARY 
Breast cancer is the most frequent and lethal cancer among women worldwide. A third of breast 
cancers can progress to metastasis, which remains the major cause of death in patients with 
solid tumors. Cells are regulated by numerous interconnected pathways, which can be 
dysregulated and results in uncontrolled proliferation. The phosphatidylinositol 3-kinase 
(PI3K) pathway is implicated in cellular growth, proliferation and survival, and is aberrantly 
activated in 70% of breast cancers. Despite the development of specific and effective drugs 
targeting the PI3K pathway, most clinical trial outcomes have been disappointing. In fact, 
mechanisms of resistance can short-circuit the efficacy of such inhibitors. Some of these 
mechanisms are receptor tyrosine kinase (RTK) driven, activating compensatory pathways and 
dramatically reducing the initial efficacy. 
Downstream of various active RTKs, Src-homology 2 domain-containing phosphatase 
(SHP2), a ubiquitously expressed protein-tyrosine phosphatase (PTP), transduces mitogenic, 
survival, cell-fate and/or migratory signals. Blockade of SHP2 has been shown to decrease 
breast tumor growth, progression and metastasis. Given that RTK-driven signaling pathways 
can overcome the effects of PI3K inhibition, and that SHP2 enhances signaling downstream of 
these receptors, we studied the effects of targeting PI3K and SHP2 simultaneously. 
 In this study, we demonstrate a fundamental effect of PI3K/SHP2 dual-inhibition in 
triple-negative breast cancers (TNBCs), a very aggressive subtype associated with poor 
prognosis. Dual inhibition targeting PI3K and SHP2 appears to be more effective than single 
inhibitions by decreasing cell number in vitro and tumor volume in vivo, as well as increasing 
cancer cell apoptosis and improving animal survival. Mechanistically, SHP2 inhibition results 
in activation of the PI3K signaling and dependency on this pathway.  
Summary 
ii 
 
We then assessed the effects of PI3K and/or SHP2 inhibitions on primary tumor growth, 
animal survival and lung metastases, a major metastatic site in breast cancer. While PI3K 
inhibition had no effects on primary tumor growth, it resulted in larger lung metastases in the 
neo-adjuvant setting. SHP2 inhibition decreased primary tumor growth as well as lung 
metastases. Both PI3K and SHP2 single treatment groups did not improve animal survival. In 
combination, PI3K/SHP2 dual-inhibition reduced synergistically primary tumor volumes, 
decreased lung metastases and increased animal survival. 
 In the adjuvant setting, PI3K and SHP2 single inhibitions, as well as PI3K/SHP2 dual-
inhibition, decreased lung metastases and increased animal survival. Despite the lack of lung 
metastases, concurrent PI3K/SHP2 blockade is not enough for complete metastasis regression. 
We demonstrated that liver metastases developed in parallel and have revealed to be insensitive 
to such inhibitions. We highlighted the discrepancy in RTK-dependences with lung metastases 
being PDGFRβ-dependant, while liver metastases are VEGFRs-dependent. Using a 
VEGFR/PDGFR inhibitor, we finally indicate that targeting PI3K/SHP2/VEGFR/PDGFR can 
further improve animal survival.  
The observations that pan-PI3K inhibition in the neo-adjuvant setting increases lung 
metastases in TNBC calls for caution when using such agents in the presence of the primary 
tumor. We have reported similar results using a dual-PI3K/mTOR inhibitor (Britschgi, 
Andraos et al. 2012). Our data provide a rationale for using pan-PI3K in combination with 
SHP2 inhibition to treat metastatic TNBC in the adjuvant setting and support further testing of 
this possibility. Moreover, we provide evidence that a triple therapy of PI3K, SHP2 and 
VEGFR/PDGFR inhibitors overcomes niche-dependent resistance and prolongs survival in 
preclinical models of TNBC. 
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3 | INTRODUCTION 
3.1 Breast cancer 
Breast cancer is the most frequent cancer among women representing 25% of all cancers 
diagnosed worldwide. The World Health Organization (WHO) measured that breast cancer is 
impacting 2.1 million women per year, and with 627,000 annual death, it represents 15% of all 
cancer losses among women (Parks, Derks et al. 2018). This heterogeneous disease is 
characterized by cancer cells that can proliferate, disseminate, survive and form metastases 
(Weigelt, Peterse et al. 2005). Initial steps of breast cancer take place in the epithelial cells of 
the mammary gland, progressing through several stages: hyperplasia, atypical ductal 
hyperplasia, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (Figure 3-1). A 
third of breast cancers progress to metastasis (Early Breast Cancer Trialists' Collaborative 
2005), the fatal hallmark of cancer (Nguyen, Bos et al. 2009), and drug resistant metastases 
remain the cause of death of most breast cancer patients (Klein 2009, Massague and Obenauf 
2016). 
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Figure 3-1 │ Breast cancer linear progression model  
Schematic view of the linear breast cancer progression. Breast cancer arises from epithelial 
cells of the mammary gland as hyperplasia, which is a benign proliferative breast condition. It 
can progress into atypical ductal hyperplasia, where the proliferating cells look abnormal, and 
may evolve into ductal carcinoma in situ, a non-invasive stage, in which the duct is filled with 
confined cancerous cells. The last and potentially lethal step of the metastatic cascade is the 
progression into invasive ductal carcinoma, in which cancer cells spread from the duct to 
surrounding tissues, to seed and colonize distant sites. 
 
Breast cancer classification is based on detection of pathological markers like the 
hormone receptors (HR), estrogen receptor (ER), progesterone receptor (PR), and the tyrosine 
kinase human epidermal growth factor receptor 2 (HER2/ERBB2), as well as clinical 
parameters such as age, tumor size, lymph node status and histological grade. However, breast 
cancer heterogeneity limits this classification. Genome-wide gene-expression profiles revealed 
6 different sub-classes: luminal A, luminal B, normal-like, HER2-enriched, basal-like and 
claudin-low with different clinical prognosis based on their aggressiveness (Perou, Sorlie et al. 
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2000, Sorlie, Perou et al. 2001, Carey, Perou et al. 2006, Prat, Parker et al. 2010). Then, copy 
number alterations (CNAs) further defined breast cancer subtypes based on the 
deoxyribonucleic acid (DNA) CNAs patterns (Hicks, Krasnitz et al. 2006). Further 
improvements led to integrative clustering using gene expression and DNA CNAs. Such 
strategy was used in the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) study, where identification of integrative clusters revealed a classification in 10 
subtypes. So far, these subtypes represent the most detailed molecular-based taxonomy of 
breast cancer (Curtis, Shah et al. 2012). In parallel, large DNA sequencing campaigns described 
the importance of driver-genes and their mutations, showing association between breast cancer 
classification and genomic drivers (e.g., TP53, PIK3CA, MYC) (Cancer Genome Atlas 2012, 
Shah, Roth et al. 2012, Stephens, Tarpey et al. 2012, Nik-Zainal, Davies et al. 2016, Pereira, 
Chin et al. 2016) 
3.2 Classification of breast cancer 
3.2.1 Luminal A and luminal B breast cancers 
Across the different subgroups, luminal tumors are characterized by the expression of ER and 
account for 60% of all breast cancers. Luminal A breast cancer cells mainly co-express ER and 
PR, while luminal B rarely co-express PR (Sims, Howell et al. 2007). These luminal tumors 
are hormone dependant and can be targeted by using endocrine therapy to block the effects of 
estrogen. Patients with luminal A breast tumors have a better response to hormonal therapy and 
longer survival compared to patients with luminal B breast tumors (Vargo-Gogola and Rosen 
2007). Beside the expression of ER and PR, this luminal subtype is also characterized by the 
overexpression of luminal markers such as the X-box binding protein 1, trefoil factor 3, 
hepatocyte nuclear factor 3 α, GATA binding protein 3 (GATA3) and estrogen-regulated LIV-
1 (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001). 
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 Since almost five decades, the ER antagonist tamoxifen has been the gold standard 
treatment of HR-positive breast cancer (Cole, Jones et al. 1971). It is a selective estrogen 
receptor modulator (SERM) that blocks the binding of estrogen to its receptor. Another strategy 
is to prevent estrogen synthesis using aromatase inhibitors, such as letrozole and anastrozole 
(Aihara, Yokota et al. 2014). This strategy has been shown to be more effective than tamoxifen 
in post-menopausal women with early-stage breast cancer leading to longer disease-free 
survival (Arimidex, Forbes et al. 2008). Other strategies include luteinizing hormone-releasing 
hormone analogs, that blocks hormone production by the ovaries (e.g., goserelin), and 
fulvestrant, a selective estrogen receptor downregulator (SERD), that degrades ER (Thompson, 
Katz et al. 1989). 
Despite this progress in endocrine therapy, a third of patients develop resistance via 
compensatory mechanisms that offsets the initial inhibition. It occurs as a result of cross-talk 
between ERs and RTKs, and with signaling pathways downstream of these receptors such as 
the PI3K-AKT-mTOR pathway (Meyer and Bentires-Alj 2010, Chen, Hsiao et al. 2017, 
Keegan, Gleeson et al. 2018). For example, upregulation of HER2, epidermal growth factor 
receptor (EGFR) or insulin-like growth factor I (IGF-I) (Arpino, Wiechmann et al. 2008, 
Musgrove and Sutherland 2009). The major consequence of these compensatory mechanisms 
is a re-expression of ER-dependent genes in absence of the ligand, resulting in the aromatase 
inhibitors being ineffective. 
Several preclinical and clinical studies have resulted in the current standard of care for 
patients with ER+ breast cancer such as the combination of letrozole with the cyclin-dependent 
kinase 4/6 (CDK) inhibitor palbociclib. This combination improves progression-free survival 
compared to single aromatase inhibition (Croxtall and McKeage 2011, Finn, Crown et al. 2015, 
Finn, Martin et al. 2016, Huang, Yang et al. 2017, Nathan and Schmid 2017).  
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Aromatase inhibitor (Letrozole, anastrozole, exemestane) or 
Selective ER modulators (Tamoxifen) or 
Selective ER down-regulator (Fulvestrant) or 
CDK4/6 inhibitor + aromatase inhibitor or 
CDK4/6 inhibitor + fulvestrant 
+ Ovarian ablation/suppression  
↓ If progression or unacceptable toxicity ↓ 
Endocrine 
refractory? 
NO Additional endocrine therapy 
YES Chemotherapy 
↓ If no clinical benefit ↓ 
Chemotherapy 
↓ If no clinical benefit ↓ 
Consider no further cytotoxic therapy and continue supportive care 
Table 3-1 │ Treatment recommendations for luminal breast cancers 
 
3.2.2 HER2-positive breast cancer 
One of the two most aggressive breast cancer subtypes, representing 15-20% of patients, is 
characterized by HER2 (or ERBB2) enriched expression. Development of the humanized 
monoclonal antibody trastuzumab improved considerably the prognosis of such patients 
(Slamon, Clark et al. 1987, Slamon, Leyland-Jones et al. 2001). Genes in this subtype vary 
based on the ER status. Many functional mutations of TP53 are found in HER2+/ER- tumors; 
while HER2+/ER+ tumors show numerous GATA3 mutations; and no subgroup prevalence for 
PIK3CA mutations (Pereira, Chin et al. 2016). Overall, two third of this subtype have HER2 
overexpression with concomitant gene amplification, while the remaining third has normal 
HER2 expression, highlighting independent HER2-amplification mechanism like HER2 
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hyperphosphorylation, truncation or splice variant (Lonardo, Di Marco et al. 1990, Scaltriti, 
Rojo et al. 2007, Alajati, Sausgruber et al. 2013). 
 Current standard of care for HER2-positive breast cancer is chemotherapy (e.g., 
paclitaxel or docetaxel) combined with the trastuzumab (herceptin) targeting the extracellular 
domain of HER2 (Baselga, Perez et al. 2006). This results in prolonged disease-free survival 
and improved outcome for early HER2-positive breast cancer patients (Romond, Perez et al. 
2005). However, 70% of HER2-positive breast cancer can develop resistance to trastuzumab, 
and further strategies are used to enhance efficacy. For example, pertuzumab prevents HER2 
dimerization, and results in a significantly prolonged overall survival and progression-free 
survival when combined to trastuzumab (Baselga and Swain 2010, Swain, Baselga et al. 2015). 
Also, trastuzumab emtansine (trastuzumab-DM1) is an antibody-drug conjugate, joining the 
HER2 cell specific targeting of trastuzumab combined to the cytotoxic activity of the 
microtubule-inhibitory agent emtansine (Junttila, Li et al. 2011, Krop, Kim et al. 2014, Krop, 
Kim et al. 2017). Tyrosine kinase inhibitors (TKIs) are also used in combination with 
trastuzumab such as lapatinib or afatinib, both targeting EGFR/HER2, or neratinib, a pan-HER 
inhibitor (Burstein, Sun et al. 2010, Hanusch, Schneeweiss et al. 2015, Xu, Zhang et al. 2017). 
Furthermore, ongoing clinical trials are evaluating the efficacy of inhibiting the heat shock 
protein 90 (HSP90), required for the stability of HER2 (Modi, Stopeck et al. 2011, Jhaveri, 
Wang et al. 2017). 
Over the last decade, the outcome of HER2-positive breast cancer patients intensely 
improved, but many patients still lack effective therapeutic solutions. Different studies are 
exploring drug combination of anti-HER2 agents with PI3K inhibitors, CDK4/6 inhibitors as 
well as immunotherapies using anti-programmed death ligand 1 (PD-L1) antibodies (Miller, 
Hennessy et al. 2010, Loibl and Gianni 2017, Shah and Cristofanilli 2017, Xu, Yu et al. 2017). 
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l Pertuzumab + trastuzumab + chemotherapy (taxane) or 
Trastuzumab emtansine (Trastuzumab-DM1) or 
Trastuzumab + chemotherapy or 
Other HER2-targeted therapies 
+ Ovarian ablation/suppression 
↓ If progression or unacceptable toxicity ↓ 
Another line of chemotherapy + HER2-targeted therapy 
↓ If no clinical benefit ↓ 
Consider no further cytotoxic therapy and continue supportive care 
Table 3-2 │ Treatment recommendations for HER2+ breast cancers 
 
3.2.3 Triple-negative breast cancer 
TNBC is named for the lack of expression of ER, PR and HER2 in these tumors and accounts 
for 10-20% of patients. This subtype includes basal-like and claudin-low breast cancers (Perou 
2011). Both share the characteristics of low expression of luminal genes clusters and luminal 
cytokeratins 9 and 18 (CKs). But, the basal-like subgroup is defined by high expression of the 
basal cytokeratins 5, 14 and 17 (Elsawaf and Sinn 2011), and the claudin-low subgroup is 
defined by high immune cells infiltration, stem cell-associated mechanisms and high epithelial-
to-mesenchymal transition (EMT) characteristics (Sims, Howell et al. 2007). In fact, these 
EMT characteristics include loss of E-cadherin, claudin 3, 4 and 7, all cell-to-cell junction 
proteins (Szasz, Nemeth et al. 2011). Of note, the term basal-like refers to a group of human 
breast cancers sharing a common signature (Sorlie, Perou et al. 2001). This does not relate to a 
basal-like tumor arising from myoepithelial cells, nor being the opposite of luminal cells 
(Gusterson and Eaves 2018). 
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 Beside surgery and radiotherapy, chemotherapy is the only option to treat TNBCs since 
they do not respond to endocrine, anti-HER2 therapy and poorly to targeted therapy. Despite 
the aggressiveness of TNBC, 30 to 40 % of patients achieve a pathological complete response 
(pCR) after chemotherapy. Detection of residual disease after neoadjuvant treatment increases 
by six the chance of relapse and by twelve the chance to succumb to metastases (Liedtke, 
Mazouni et al. 2008, Esserman, Berry et al. 2012, Gluck, Ross et al. 2012, Masuda, Baggerly 
et al. 2013). Recently, poly ADP ribose polymerase (PARP) has been approved for the 
treatment of patients with HER2-negative metastatic breast cancer and a germline BRCA 
mutation and brings a significant benefit over the standard therapy (Robson, Im et al. 2017). 
The increased knowledge of the biology of these tumours over the last 5 years has led to new 
clinical trials to test the anti-vascular endothelial growth factor (VEGF) monoclonal antibody 
bevacizumab; multi-target inhibitor like sunitinib targeting VEGF Receptor (VEGFR), 
platelet-derived growth factor receptor (PDGFR) and c-KIT; as well as inhibitors of EGFR, 
PI3K and CDK1/2 (Mitri, Karakas et al. 2015, Nakai, Hung et al. 2016, Costa, Han et al. 2018).  
  
Introduction 
- 9 - 
 
Non-metastatic 
TNBC 
Cycles of anthracycline-
taxane chemotherapy 
1st 
Epirubicin or 5-fluorouracil  
or cyclophosphamide 
2nd Paclitaxel or docetaxel 
Metastatic 
TNBC 
Platinum-
based 
chemotherapy 
- Cisplatin or oxaliplatin or carboplatin 
BRCA1/2 
mutation 
Cisplatin + PARP inhibitors 
↓ If progression or unacceptable toxicity ↓ 
Another line of chemotherapy 
↓ If no clinical benefit ↓ 
Consider no further cytotoxic therapy and continue supportive care 
Table 3-3 │ Treatment recommendations for TNBC breast cancers 
 
3.3 Dissemination and colonization of metastatic cells 
3.3.1 Metastatic cascade 
Cancer is a lethal disease that can, from the primary tumor, migrate and grow in secondary 
distant sites. This process is called metastasis. It remains a major challenge since 90% of deaths 
are caused by drug resistant metastases in patients with solid tumors (Early Breast Cancer 
Trialists' Collaborative 2005, Gupta and Massague 2006). Dissemination of cancer cells starts 
at an early stage of tumor progression, but remains an inefficient process since 99.98% of cells 
leaving the primary tumor die before forming a metastasis (Valastyan and Weinberg 2011, 
Massague and Obenauf 2016). In fact, a primary tumor consists of millions of cells, but very 
few will penetrate the circulatory system, and even fewer will survive in circulation and form 
distant lesions. Furthermore, cancer cells that successfully penetrated and niched in distant 
organs can reside as dormant micrometastases that may or may not form macrometastases, 
termed metastatic latency or metastatic dormancy (Luzzi, MacDonald et al. 1998, Kienast, von 
Baumgarten et al. 2010, Giancotti 2013).  
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Dissemination of metastatic cells is a multi-step process. Initial steps are the local 
invasion and migration of primary tumor cells, promoted by cytoskeletal rearrangements, cell-
to-cell interactions, secretion of matrix metalloproteinases (MMPs) and various cathepsins 
(Kessenbrock, Plaks et al. 2010). Cancer cells have then the capacity to migrate in the 
extracellular matrix, as single cell or collectively. Surrounding stromal cells can secrete 
transforming growth factor-β (TGF-β) leading to EMT of cancer cells, resulting in phenotypic 
changes and enhanced invasiveness (Thiery, Acloque et al. 2009). EMT can promote 
intravasation of cancer cells (i.e., entering the circulatory system), while reversal of this state 
can favour extravasation and support colonization. However, the EMT process is not required 
in all situations, since breast and prostate cancers can invade in an EMT-independent manner 
(Fischer, Durrans et al. 2015, Zheng, Carstens et al. 2015). 
In the blood stream, circulating tumor cells (CTCs) can be found as single cells or 
clusters. This multi-cell state results in an advantage over single cells to form metastatic lesions 
(Aceto, Bardia et al. 2014, Szczerba, Castro-Giner et al. 2019). In fact, metastatic lesions are 
made of multiclonal seeding, suggesting a collection of subclones capable of colonizing 
metastatic sites (Hoadley, Siegel et al. 2016, Turajlic and Swanton 2016, Turajlic, Xu et al. 
2018). Cancer cells need to resist to the immune system, while copping shear forces and 
oxidative stress (Gay and Felding-Habermann 2011, Le Gal, Ibrahim et al. 2015). Their 
dissemination relies on blood vessels architecture, capillary wall properties and mechanical 
constrictions of the visited organs. CTCs trapped in a microvessel can potentially grow and 
rupture the vessel, or extravasate (Hong, Li et al. 2016). Metastases initiating cells need to 
survive multiple selective pressure such as the immune system, foreign environment while still 
retaining capacity to proliferate. This step can last several years and cells survive as 
disseminated tumor cells (DTCs) (Pantel and Brakenhoff 2004) (Figure 3-2). Breast cancer 
metastases are found in bone, lung, liver and brain (Chiang and Massague 2008). ER+ breast 
Introduction 
- 11 - 
 
cancer predominantly form bone metastases; TNBC form metastases in the brain and lungs; 
and, while anti-HER2 therapy improved HER2+ patient survival, brain metastases remain 
challenging for this subtype (Chiang and Massague 2008, Dent, Hanna et al. 2009, Kennecke, 
Yerushalmi et al. 2010). 
 
Figure 3-2 │ Metastatic progression 
Primary tumor cells invade locally (1). The EMT process can support cell intravasation (2) of 
surrounding tissues or newly formed blood vessels (3). Mechanical constrictions will stop their 
route in most cases, as single cells or clusters (4), allowing a possible intravasation through the 
vascular wall (5). If disseminated cells survive in their new environment, they may remain as 
micrometastases (dormancy) or grow into macrometastases (6). 
 
 One commonly admitted model consider cancer cells to arise from cells that conserved 
their tumor initiating capacity (Kleinsmith and Pierce 1964, Al-Hajj, Wicha et al. 2003). Once 
these cells reached a secondary site, they might benefit from the niche characteristics that can 
be in some situation similar to their original niche. Also, they can produce their own niche such 
as lung-metastatic breast cancer cells producing the extracellular-matrix protein tenascin C, 
amplifying proliferative pathways such as Notch and Wnt (Oskarsson, Acharyya et al. 2011). 
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Additionally, recent studies show that metastatic lesions can further generate CTCs and new 
distant lesions, suggesting a continuous and dynamic dissemination (Gundem, Van Loo et al. 
2015). 
3.3.2 Disseminated tumor cells  
Treatments are administered after surgery to specifically target disseminated cells (adjuvant 
treatment). DTCs remain very difficult to detect (Chapman, Webster et al. 2013) and can 
display several cellular states. In fact, it is commonly admitted that metastatic latency is the 
result of a delayed adaptation to the new microenvironment, worsen by poor neoangiogenesis, 
immune surveillance and therapeutic pressure (Holmgren, O'Reilly et al. 1995, Eyles, Puaux et 
al. 2010, Davies, Pan et al. 2013). Adjuvant therapies show high efficacy in ER+ and HER2+ 
breast cancer, based on five years survival. Beyond this timeframe, the risk of relapse remains 
important, due to the lack of sensitivity of dormant and non-proliferative DTCs to treatment 
(Di Cosimo and Baselga 2010, Zhang, Giuliano et al. 2013, Sledge, Mamounas et al. 2014). 
However, once metastases become clinically manifest, therapeutic solutions vary based on the 
organ site (e.g., for liver metastases, standard of care can be hepatectomy, liver transplantation 
or targeted therapy with sorafenib) (Early Breast Cancer Trialists' Collaborative 2015). 
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3.4 Phosphatases and kinases in cancer 
Most cellular processes are regulated by signaling pathways in eukaryotic cells. Protein 
phosphorylation is a crucial post-translational modification in signal transduction (Hunter 
1995). It occurs at specific sites and is mediated by protein kinases, that add a phosphate group, 
and by protein phosphatases, that remove it. 
The phosphorylation process results in conformational changes that influence protein 
activity with the apparition of docking sites. This enable binding to other proteins and 
formation of signaling complexes. Phosphorylation of serine (Ser), threonine (Thr) and 
tyrosine (Tyr) represent 17% of the total-human-proteome, named phospho-proteome (Sharma, 
D'Souza et al. 2014). Within the 230,000 phospho-sites existing in human proteins, the ratio 
between serine/threonine/tyrosine has been estimated to be 90/10/0.05 (Hunter and Sefton 
1980, Vlastaridis, Kyriakidou et al. 2017). Abnormal tyrosine phosphorylation, despite its low 
representation, causes a plethora of human diseases including cancer (Gschwind, Fischer et al. 
2004, Hunter 2009, Du and Lovly 2018). This led to extensive research on protein tyrosine 
kinases (PTKs) over the last decades. PTPs were left aside for a substantial time, as they were 
considered as attenuating effectors with a little selectivity. Nowadays, PTKs and PTPs are both 
recognized as major actors in phosphorylation of tyrosine residues (Figure 3-3). 
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Figure 3-3 │ Schematic of substrate phosphorylation by PTKs and PTPs 
Proteins can be phosphorylated on tyrosine residues by PTKs and reversely, can be 
dephosphorylated by PTPs. Tyrosine phosphorylation is crucial in eukaryotic cells and 
dysregulations can lead to a plethora of diseases. Furthermore, proteins have several 
phosphorylation sites, resulting in a multi-modal protein state based on their phosphorylation 
status (P: phosphate). 
 
3.5 Protein tyrosine phosphatases 
Compared to protein kinases, PTPs did not evolve from a common ancestor, but from two 
distinct families defined by their structures and mechanisms. These families are the classical 
PTPs dephosphorylating only tyrosine residues; and the dual-specificity PTPs 
dephosphorylating serine, threonine or tyrosine residues (Tonks 2006). Within the classical 
PTP family, 37 are encoded in the human genome, sub-divided into receptor-like PTPs and 
non-transmembrane or intracellular PTPs (Andersen, Mortensen et al. 2001) (Figure 3-4). 
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Figure 3-4 │ The classical PTPs family 
The classical PTPs family is composed of 37 different members in human, and is sub-divided 
into receptor-like PTPs (left) and non-transmembrane PTPs (right). The receptor-like PTPs 
contain an intracellular PTP domain, consisting of the catalytic-site motif HC(X)5R, a 
transmembrane domain and various types of extracellular domains involved in cell-cell, cell-
matrix and cell-ligand interactions. The intracellular PTPs are considerably much diverse in 
structures with a PTP domain, and domains such as SH2 and FERM targeting them specifically 
to cellular locations or adapter proteins. Nevertheless, this separation into two families is not 
absolute since alternative promoters or splicing can result in transmembrane and cytoplasmic 
forms of some PTPs. 
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The PTP family dephosphorylates their substrate by a similar mechanism. The active 
site sequence VHCSXGXGR[T/S]G demarcates the PTP family and is commonly named “PTP 
loop” or “PTP signature motif”. At the basis of the active site cleft, residues of this motif 
constitute the phosphate-binding loop (Andersen, Mortensen et al. 2001). The cysteine in the 
PTP loop (Cys459 in SHP2) acts as a nucleophile and accepts phosphate transiently during the 
catalysis. Firstly, the sulfur atom of the thiolate ion of cysteine attacks the phosphorous atom 
of the substrate phosphate group. The P-O linking the phosphate group to the tyrosine is 
protonated by a conserved aspartic acid (Asp425 in SHP2). This aspartic acid resides in the 
WPD-loop and is brought in close proximity by a conformational change of the protein upon 
substrate binding. Secondly, hydrolysis of the phosphoenzyme intermediate by a water 
molecule and the aspartic acid, functioning as a general base, results in the release of the 
phosphate (Figure 3-5).  
 
Figure 3-5 │ Catalytic mechanism of cysteine-based PTPs 
Schematic representation of the general two-step mechanism of the PTP-catalyzed reaction, in 
which the catalytic cysteine (Cys459 in SHP2) is part of the signature motif HC(X)5R located 
in the phosphate-binding loop. The catalytic cysteine attacks the phosphate of the substrate as 
a nucleophile and is needed to catalyse the hydrolysis of the phosphoester bond via a 
phosphate-cysteine intermediate. The conserved aspartic acid (Asp425 in SHP2), located in the 
WPD-loop, functions as the general acid/base during hydrolysis (Brandao, Hengge et al. 2010). 
 
The PTP specificity relies on the active site pocket shape and is determinant for the 
substrate recognition (Kim and Ryu 2012). This specificity gives the depth between the 
molecular surface and the phosphate-binding loop (P-loop), which is 9 Å for SHP2, considered 
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as deep since the catalytic cleft is located at the base of the P-loop. This depth is characteristic 
for proteins with phospho-tyrosines residues, and non-specific for shorter phospho-serine or 
phospho-threonine side-chains (Jia, Barford et al. 1995). 
3.5.1 The oncogenic tyrosine phosphatase SHP2 
The tyrosine phosphatase SHP2, encoded by PTPN11, also known as Syp, SH-PTP2, SH-
PTP3, PTP1D or PTP2C has been identified in the 1990’s (Adachi, Sekiya et al. 1992, 
Freeman, Plutzky et al. 1992, Ahmad, Banville et al. 1993, Feng, Hui et al. 1993, Vogel, 
Lammers et al. 1993). This PTP is ubiquitously expressed and can bind several RTKs to 
transduce mitogenic, pro-survival, cell fate, pro-migratory signals downstream of numerous 
stimuli such as cytokines, growth factors and extracellular matrix components (Sausgruber, 
Coissieux et al. 2015, Matalkah, Martin et al. 2016).  SHP2 is required for the full activation 
of the mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) 
pathway (Klinghoffer and Kazlauskas 1995, Montagner, Yart et al. 2005, Aceto, Sausgruber et 
al. 2012, Bunda, Burrell et al. 2015). It has also been shown that SHP2 can activate or inactivate 
other pathways such as Janus kinase (JAK)-signal transducer and activator of transcription 
protein (STAT) and the PI3K pathway, based on the cellular type and receptors involved 
(Berchtold, Volarevic et al. 1998, Zhang, Tsiaras et al. 2002, Mattoon, Lamothe et al. 2004, 
Xu and Qu 2008). 
 The protein phosphatase SHP2 is composed of two SRC homology 2 (SH2) domains 
(also named N-SH2 and C-SH2), a PTP catalytic domain and a proline-rich motif on the C-
terminal tail, with two tyrosyl phosphorylation sites located at tyrosine 542 and tyrosine 580 
(Chan, Kalaitzidis et al. 2008) (Figure 3-6). 
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Figure 3-6 │ Schematic representation of the protein tyrosine phosphatase SHP2  
The protein tyrosine phosphatase SHP2 is composed of two N-terminal tandem SH2 domains, 
a catalytic phosphatase domain (PTP), and a C-terminal tail containing a proline-rich motif 
(not shown) and two tyrosyl residues Y542 and Y580. 
 
SHP2 oscillates between two structural conformations, unveiling/hiding the PTP 
domain. In the absence of upstream stimulation, the phosphatase SHP2 is in an autoinhibition 
inactive state due to the binding of the N-SH2 domain with the PTP domain (Hof, Pluskey et 
al. 1998) (Figure 3-7). Upon stimulation, RTKs, cytokine receptors or scaffolding proteins will 
be phosphorylated on specific tyrosines that can be bound by the SH2 domains of SHP2. These 
adapter proteins can be the growth factor receptor-bound protein 2 (GRB2), GRB2-associated-
binding protein 1 (GAB1) and GRB2-associated-binding protein 2 (GAB2). This binding will 
change the conformational structure of SHP2, release the PTP domain from its inhibition and 
result in an active enzyme that can dephosphorylate its substrate (Cunnick, Mei et al. 2001, 
Chan, Kalaitzidis et al. 2008) (Figure 3-7). 
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Figure 3-7 │ Schematic of the mechanism of SHP2 activation 
The protein tyrosine phosphatase SHP2 can be found in an inactive state, held by the binding 
of the N-SH2 domain to the PTP domain, in an autoinhibition state (left). Upon stimulation, 
specific phospho-tyrosines will be bound by the SH2 domains of SHP2, leading to a 
conformational change and release of the autoinhibition state (right). This results in an open 
conformation of SHP2 and a PTP domain that can dephosphorylate substrates (P: phosphate). 
 
Mainly all effects of SHP2 have been studied in the context of its PTP catalytic activity, 
and very few about its PTP-independent properties. For examples, it has been shown that 
SHP2-phosphatase-dead can activate STAT transcription, SRC tyrosine kinases, the PI3K 
pathway via IL-3 induction, and prevent p53-mediated apoptosis in the brain and neural crest 
via its SH2 domains (Berchtold, Volarevic et al. 1998, Walter, Peng et al. 1999, Yu, Hawley 
et al. 2003, Stewart, Sanda et al. 2010). 
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3.5.2 Effects of SHP2 in normal tissue and disease 
The ubiquitously expressed phosphatase SHP2 is required for development in a large panel of 
species as shown by loss-of-function (LOF) or loss-of-expression of SHP2 studies in nematode, 
fly, zebrafish, xenopus and mouse. For example, SHP2 is necessary for gastrulation in mice 
(Arrandale, Gore-Willse et al. 1996, Saxton, Henkemeyer et al. 1997, Saxton and Pawson 
1999). Studies on embryonic stem cells show that lack of SHP2 blocks their differentiation into 
the three germ layer cell lineages (ectoderm, endoderm and mesoderm) in human and in mice 
(Wu, Pang et al. 2009). Based on the notion that SHP2 is important for self-renewal, it has been 
extended to a larger number of progenitors and stem-cells, positioning SHP2 as a key factor in 
organ morphogenesis (Chan, Cheung et al. 2011, Heuberger, Kosel et al. 2014, Zhou, Deng et 
al. 2015). Also, SHP2 is expressed in hematopoietic cells and involved in lineages of blood 
cells. Upon SHP2 inactivation, severe loss of erythroid, myeloid and lymphoid populations 
occurs (Qu, Nguyen et al. 2001, Chan, Cheung et al. 2011). 
 Germline missense GOF mutations have been identified in about 40% of patients with 
Noonan syndrome (NS) (Tartaglia, Mehler et al. 2001). NS is associated with crano-facial 
dysmorphia, cardiopathies, mental retardation, short stature, increased risk of leukemia and 
occurs in 1 per 1,000-2,500 live births (Mendez and Opitz 1985). The mutations causing NS, 
often occur in exon 3 and 8, interrupt the autoinhibition between the PTP domain and the N-
SH2, and result in a constitutively active form of SHP2 (Zheng, Alter et al. 2009) (Figure 3-
8). 
The multiple lentigines, electrocardiographic abnormalities, ocular hypertelorism, 
pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness 
(LEOPARD) or LEOPARD syndrome (LS), named today as Noonan syndrome with multiple 
lentigines (NS-LM), is also a polymalformative autosomal dominant genetic syndrome, in 
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which 90% of the patients display a mutation in PTPN11. These mutations often occur in exon 
7 and 12, coding for the PTP domain, and result in LOF. They give rise to a dominant negative 
form of SHP2 (Digilio, Conti et al. 2002, Legius, Schrander-Stumpel et al. 2002, Zheng, Alter 
et al. 2009) (Figure 3-8).  
 
Figure 3-8 │ SHP2 mutations result in human diseases 
The protein tyrosine phosphatase SHP2 is subject of mutations leading to diseases. Gain-of-
function mutations (left) have been described in leukemia and Noonan syndrome with a 
constitutively activated form of SHP2, while loss-of-function mutations (right) cause Noonan 
syndrome with multiple lentigines, due to a dominant negative form of SHP2. 
 
Phenotypically, NS-LM is close to NS, but some symptoms are specific such as 
cutaneous defects and deafness. The catalytically defective form of SHP2 interferes with 
signaling. For example, it decreases growth factor-induced activation of the ERK pathway 
(Kontaridis, Swanson et al. 2006). The exact mechanism leading to NS-LM remain largely 
debated (Edouard, Montagner et al. 2007, Yart and Edouard 2018). It has been proposed that a 
preferential recruitment of the catalytically-impaired form of SHP2 prevents the wild-type form 
for activating the MAPK pathway (Kontaridis, Swanson et al. 2006, Qiu, Wang et al. 2014). 
Alternatively, the focal adhesion kinase (FAK), substrate of SHP2, remains hyper-
phosphorylated and activates the PI3K pathway in response to EGF in hypertrophic heart and 
insulin-sensitive tissues of mouse models (Ishida, Kogaki et al. 2011, Marin, Keith et al. 2011, 
Schramm, Fine et al. 2012, Tajan, Batut et al. 2014).  
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3.5.3 SHP2 in cancer  
SHP2 is the first bona fide PTP proto-oncogene, and its effects in cancer are essentially non-
genetic (Chan and Feng 2007). SHP2 can be activated in cancer by two means: GOF or 
downstream of oncogenes. In myeloid malignancies, 35% of juvenile myelomonocytic 
leukemias (JMML) are caused by PTPN11 somatic GOF point mutations, mostly by disrupting 
the N-SH2/PTP interaction that results in increased SHP2 activity (Tartaglia, Niemeyer et al. 
2003, Keilhack, David et al. 2005, Niihori, Aoki et al. 2005). SHP2 mutations are also found 
in acute myeloid leukemia (AML), sporadic juvenile myelomonocytic leukemia, 
myelodysplastic syndrome and acute B lymphoblastic leukemia (Tartaglia, Niemeyer et al. 
2003, Loh, Reynolds et al. 2004, Loh, Vattikuti et al. 2004). In rare cases, SHP2 mutations are 
also found in solid tumors such as neuroblastoma, lung cancer and gastric cancers (Bentires-
Alj, Paez et al. 2004).  
Since SHP2 is a signal transducer downstream of numerous RTKs, it is central for 
transformation initiated by RTK mutations or amplifications. SHP2 has been shown to be 
involved in progression of laryngeal, breast and pancreatic cancers, as well as in malignant 
glioblastomas (GBM) (Bentires-Alj, Gil et al. 2006, Liu, Feng et al. 2011, Aceto, Sausgruber 
et al. 2012, Gomes, Connelly et al. 2013, Gu, Han et al. 2014, Hu, Fang et al. 2014, Sausgruber, 
Coissieux et al. 2015). SHP2 has been shown to mediate signaling downstream of hepatocyte 
growth factor receptor (HGFR/c-Met), fibroblast growth factor receptor 1 (FGFR1) and EGFR 
(Matalkah, Martin et al. 2016). Furthermore, the scaffolding adapter GAB2, amplified in 10-
15% of human breast tumors, results in the hyperactivation of the SHP2-ERK pathway, 
increased proliferation and invasiveness  (Bentires-Alj, Gil et al. 2006, Banerji, Cibulskis et al. 
2012, Stephens, Tarpey et al. 2012).  
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Inappropriate activation of SHP2 has been described in gastric cancer caused by 
Helicobacter pylori, encoding several determinants including the CagA gene. This protein can 
be phosphorylated by SRC-family kinases on the C-terminal EPIYA motif, leading to the 
recruitment and activation of SHP2, mimicking a GAB scaffolding adaptor (Higuchi, Tsutsumi 
et al. 2004). Gastric epithelial cells infected with H. pylori or transfected with CagA display a 
characteristic phenotype termed “hummingbird phenotype”, which is reverted by PTPN11 
deletion (Higashi, Tsutsumi et al. 2002, Tsutsumi, Higashi et al. 2003). This phenotype is the 
result of MAPK pathway hyperactivation, FAK dephosphorylation, and inhibition of the 
polarity kinase Prader-Willi/Angelman region-1 (PAR1) resulting in cellular polarity defects 
(Tsutsumi, Takahashi et al. 2006, Saadat, Higashi et al. 2007, Lu, Murata-Kamiya et al. 2009). 
Contrary to the above-mentioned proto-oncogenic effects, SHP2 has been proposed as 
a tumor suppressor in liver. SHP2 deletion promotes inflammatory signaling and hepatic 
necrosis, leading to tumor development (Bard-Chapeau, Li et al. 2011, Han, Xiang et al. 2015). 
Similar observations have been shown in cartilage, in which SHP2 deletion leads to 
metachondromatosis (e.g., exostoses, enchondromas, joint destruction and bony deformities) 
(Yang, Wang et al. 2013). 
3.5.4 SHP2 inhibitors 
For years selective inhibitors of SHP2 were lacking and most studies relied on shRNA or 
knockout mice (Bard-Chapeau, Li et al. 2011, Aceto, Sausgruber et al. 2012). The recent 
development of selective SHP2 inhibitors facilitated the advancement of the field, with notably 
the discovery of a potent allosteric SHP2 inhibitor, with high efficacy to block proliferation in 
several RTK-driven human cancers (Tautz and Mustelin 2007, Zhang, He et al. 2010, Chen, 
LaMarche et al. 2016, Garcia Fortanet, Chen et al. 2016). A first in human (FIH) clinical trial 
has been initiated to characterize the tolerability and the safety of the SHP2 inhibitor TNO155 
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in EGFR mutant NSCLC, esophageal squamous cell cancer (ESCC), head-and-neck squamous 
cell cancer (HNSCC) on a rat sarcoma/rapidly accelerated fibrosarcoma (RAS/RAF) wild-type 
background (NCT03114319). 
These new molecules facilitated mechanisms of resistance studies by blocking SHP2 
simultaneously with other targets. In non-small-cell lung cancer (NSCLC), SHP2 inhibition 
restored sensitivity to anaplastic lymphoma kinase (ALK) inhibition and to mitogen-activated 
protein kinase kinase (MEK) inhibition in Kirsten rat sarcoma virus (KRAS)-mutant NSCLC 
(Dardaei, Wang et al. 2018, Fedele, Ran et al. 2018, Mainardi, Mulero-Sanchez et al. 2018, 
Ruess, Heynen et al. 2018). In TNBC with RAS mutations at G12, combinatorial targeting of 
SHP2 and components of ERK signaling prevents adaptive resistance (Ahmed, Adamopoulos 
et al. 2019). 
3.6 Protein tyrosine kinases 
The proteome is subject to post-translational modifications including glycosylation, 
nitrosylation, acylation, ubiquitination, lipidation, methylation, proteolysis and 
phosphorylation (Walsh, Garneau-Tsodikova et al. 2005, Duan and Walther 2015). Kinases 
conduct the phosphorylation reaction, catalysing the transfer of phosphate groups on ATP to 
residues of proteins. Various kinases are found in eukaryotic cells such as the serine/threonine 
kinases, the PTK, and the tyrosine and threonine kinases, also named dual-specificity protein 
kinases (Cohen 2002, Kennelly 2002, Ubersax and Ferrell 2007, Kannan and Taylor 2008). 
The human kinome contains 518 genes coding for protein kinases, able to phosphorylate nearly 
a third of the proteome (Hanks and Hunter 1995, Cohen 2000, Hunter 2000, Ficarro, 
McCleland et al. 2002, Manning, Whyte et al. 2002). 
The PTKs form a large family, with the principal effect is the regulation of numerous 
cellular aspects such as cell growth signaling, differentiation, proliferation, adhesion, motility 
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and death (Hunter and Cooper 1985). The human genome analysis shows 90 genes encoding 
for PTKs. They are subdivided as RTKs (58 genes; e.g., EGFR, PDGFR, VEGFR) and non-
RTK (NRTK) (32 genes; e.g., Abelson murine leukemia viral oncogene homolog 1 (ABL1), 
Src kinase family). Dysregulation of this phosphorylation processes lead to a large number of 
human diseases including cancer, diabetes and congenital syndromes (Blume-Jensen and 
Hunter 2001, Cohen 2002, Drake, Lee et al. 2014, Jiao, Bi et al. 2018). Four decades of research 
have considerably increased insights on their structures, functions and regulation, from gene 
characterization to protein structure.  
For 50% of the cases in cancer, proto-oncogene and oncogenes effects result in 
abnormal PTK activities, driving tumorigenesis (Blume-Jensen and Hunter 2001). Due to the 
significant implication of PTKs in human diseases, they became a very important target in drug 
research. The previously cited lapatinib, a reversible dual inhibitor of EGFR and HER2, is 
approved by the Food and Drug Administration (FDA) since 2007 for the treatment of breast 
cancer, NSCLC, head and neck cancer and gastric cancer (Hicks, Macrae et al. 2015). Several 
multi-target kinase inhibitors are approved such as sorafenib, inhibiting PDGFRs/VEGFRs/Raf 
family kinases and prolongs progression-free survival of patients with kidney cancer (Bolondi, 
Craxi et al. 2015); or also sunitinib, inhibiting PDGFRs/VEGFRs/c-KIT, approved for 
inoperable renal cell carcinoma (RCC) (Kalra, Rini et al. 2015). 
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3.7 Phosphoinositol 3-Kinase signaling 
3.7.1 PI3K classification and signaling 
Eukaryotic cells have an additional family of kinases phosphorylating small molecules, 
including lipids. The PI3K is a family of lipid kinases involved in cell growth, proliferation, 
survival and metabolism. It is composed of regulatory units p85α, p85β, p50α, p55α, p55γ, and 
catalytic units p110α, p110β, p110γ or p110δ. They are subdivided in three classes based on 
their structure, substrate affinities, sequence homology, while having distinct cellular effects. 
The class I PI3Ks preferentially phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) 
to phosphatidylinositol-3,4,5-trisphosphate (PIP3), and are themselves split in two groups 
based on the upstream mode of activation: the class IA PI3Ks are activated by RTKs; the class 
IB by G-protein-coupled receptors (GPCRs) (Figure 3-9). 
 
Figure 3-9 │ Schematic overview of class I PI3K catalytic and regulatory subunits 
Domain structures of class I PI3K subunits, phosphorylate preferentially PIP2 to PIP3. The 
class IA are activated by RTKs; the class IB by GPCRs. Among the different possible 
interactions, p110α and p85α have tight binding between their ABD and i-SH2 domains, 
conferring stability to p110α. Also, N-SH2 decreases basal activity by interactions to the 
helical, kinase and C2 domains. These inhibitions are released upon binding to phospho-
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tyrosines (ABD: adaptor-binding domain; RBD: Ras-binding domain; BH: breakpoint cluster 
region homolog). 
 
The catalytic subunit p110 is ubiquitously expressed in human tissues except p110γ and 
p110δ that are enriched in immune cells. The regulatory subunit p85 interferes with the p110 
kinase activity. Upon growth factor binding, RTKs are activated by autophosphorylation, 
leading to the recruitment of the p85 subunit to the newly activated RTK, or to associate adapter 
proteins. This binding releases the p110 catalytic subunit which translocates to the nearby 
plasma membrane, phosphorylates PIP2 to PIP3, resulting in the activation of numerous 
downstream effectors such as the phosphoinositide-dependent kinase 1 (PDK1), mammalian 
target of rapamycin complex 2 (mTORC2), AKT (also called protein kinase B), tuberous 
sclerosis complex (TSC), mammalian target of rapamycin complex 1 (mTORC1) and p70 
ribosomal protein S6 kinase (S6K) (Staal 1987, Whitman, Downes et al. 1988, Auger, Serunian 
et al. 1989, Heitman, Movva et al. 1991, Jones, Jakubowicz et al. 1991, Manning and Toker 
2017). PIP3 is transiently induced and is metabolized by lipid phosphatases, notably the 
phosphatase and tensin homolog (PTEN), that removes the 3’-phosphate from PIP3 and 
terminates PI3K signaling (Maehama and Dixon 1998) (Figure 3-10). 
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Figure 3-10 │ Schematic of the activation mechanism of class IA PI3Ks 
Upon ligand binding to a RTK, the phosphorylation of the receptor (or associated adaptors, not 
shown) creates docking sites for the p85 subunit. Binding of this subunit to a phospho-tyrosine 
releases the p110 catalytic subunit, leading to its translocation at the plasma membrane, 
enabling the phosphorylation of PIP2 to PIP3. This will attract downstream effectors such as 
PDK1, mTORC2, AKT, TSC and S6K, and activate cellular processes involved in 
proliferation, growth, death and metabolism. Activation of the PI3K signaling is ended by the 
conversion of PIP3 to PIP2 by the lipid phosphatase PTEN.  
 
Class II PI3Ks can phosphorylate phosphatidylinositol, but also phosphatidylinositol-
4-phosphate (PI-4-P) in rarer cases. Finally, class III are essentially involved in membrane 
trafficking and autophagy, and composed of human vacuolar protein sorting 34 (hVPS34), 
initially found in yeast as Vps34 (Schu, Takegawa et al. 1993, Wurmser, Gary et al. 1999, 
Backer 2016). 
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3.7.2 Dysregulation of PI3K signaling in cancer 
The PI3K pathway is among the most frequently activated pathway in human cancer, and is 
hyperactivated in 70% of breast cancers (Saal, Holm et al. 2005, Stemke-Hale, Gonzalez-
Angulo et al. 2008). Often, these dysregulations are within class I PI3Ks, more especially 
PIK3CA, the gene encoding for the p110α subunit. PIK3CA is amplified and/or mutated in 
several human solid tumors like GBM, breast, colorectal and lung cancers (Bachman, Argani 
et al. 2004, Samuels, Wang et al. 2004, Levine, Bogomolniy et al. 2005, Wu, Xing et al. 2005, 
Kadota, Sato et al. 2009). In breast cancer, dysregulations of PIK3CA is found in 30% of 
patients at all stages (Bachman, Argani et al. 2004, Samuels, Wang et al. 2004, Saal, Holm et 
al. 2005, Barbareschi, Buttitta et al. 2007, Miller 2012).  
Major mutations are found on two hot spots, located in the helical domain (exon 9, 
E542K, E545K) with 33% occurrence, and in the kinase domain (exon 20, H1047R) with 47% 
occurrence, both resulting in a constitutively active form of p110α (Samuels, Wang et al. 2004). 
PIK3CA mutations lead to uncontrolled growth and survival. These mutants of p110α are found 
in luminal, HER2+ and TNBC breast cancers, while their correlation to pathological 
parameters is so far debated (Bachman, Argani et al. 2004, Saal, Holm et al. 2005, Mukohara 
2015, Sobhani, Roviello et al. 2018). In rare cases, mutations are found in other catalytic 
subunits like p110β (helical domain, exon 11, E633K), important for breast cancer initiation 
by increased activity of the subunit; or p110γ, found in invasive breast carcinoma (Benistant, 
Chapuis et al. 2000, Ciraolo, Iezzi et al. 2008, Jia, Liu et al. 2008, Xie, Abel et al. 2013). Very 
limited studies report alterations of other PI3K family members such as class II and class III 
(Maffucci, Cooke et al. 2005, Hirsch, Shen et al. 2010, Chikh, Ferro et al. 2016). 
Mutations in the p85α regulatory subunit of class I PI3Ks, encoded by PIK3R1, have 
been found in endometrioid endometrial cancers (EEC), GBMs, ovarian, colon and breast 
Introduction 
- 30 - 
 
tumors (3%) (Parsons, Jones et al. 2008, Urick, Rudd et al. 2011, Mukohara 2015). Mutations 
are clustering within the p85α inter-SH2 domain, decreasing the inhibitory effect on the p110α 
subunit, and promoting phosphorylation of AKT at Ser473 (Jaiswal, Janakiraman et al. 2009, 
Wu, Shekar et al. 2009, Sun, Hillmann et al. 2010). Other mutations on PIK3R1 and PIK3R2 
can decreases the stability of the lipid phosphatase PTEN, increasing PI3K pathway activity 
(Cheung, Hennessy et al. 2011). 
PTEN is frequently lost in various cancers, with a chromosome 10q deletion, including 
PTEN region, found in 24-58% of invasive urothelial carcinomas (Knowles, Platt et al. 2009, 
Bunney and Katan 2010) and in 30% breast cancers (Stemke-Hale, Gonzalez-Angulo et al. 
2008). Other lipid phosphatases are involved in cancer such as SH-2 containing inositol 5' 
polyphosphatase 1 (SHIP-1), encoded by INPP5D, with a correlated reduction in chronic 
myeloid leukemia (CML), or SHIP-2, encoded by INPPL1, with an increased expression in 
several breast cancer cell line models (Bunney and Katan 2010). 
The genes encoding AKT have been found mutated in cancer. For example, AKT1 
(E17K) occurs at low frequency in luminal and ER+ breast cancers (1.5%-9%) and leads to a 
constitutive localization and active state at the membrane, regardless of stimulation inputs 
(Carpten, Faber et al. 2007). Moreover, AKT2 mutations (2.8%) correlate with breast cancer 
aggressiveness and poor prognosis (Bellacosa, de Feo et al. 1995, Cheng, Ruggeri et al. 1996, 
Saal, Holm et al. 2005).  
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3.7.3 PI3K inhibitors 
The high importance of PI3K-AKT-mTOR pathway in cancer progression led to the 
development of inhibitors targeting the pathway with various approaches, with nearly 40 
compounds reaching different stages of clinical development. The PI3K pathway can be 
blocked using mTOR, AKT or PI3K inhibitors. Few of them are approved such as mTORC1 
inhibitors temsirolimus and everolimus, the pan-PI3K inhibitor copanlisib and the PI3Kδ 
inhibitor idelalisib (Hudes, Carducci et al. 2007, Motzer, Escudier et al. 2008, Patnaik, 
Appleman et al. 2016). 
 Due to the plurality of PI3K subunits, various inhibition strategies have been 
investigated. Pan-PI3K inhibition targets all four PI3K class I isoforms. This leads to a broad 
and effective inhibition on tumors with high levels of PIP3. As of today, only copanlisib is 
approved for the treatment of lymphomas (Dreyling, Santoro et al. 2017). In fact, clinical trials 
of pan-PI3K inhibitors are often discontinued due to insufficient efficacy, toxicities and lack 
of biomarkers for clinical activity assessment (Liu, Cheng et al. 2009). In breast cancer, 
buparlisib has been proven effective in two phase II studies, but has been discontinued for 
psychiatric adverse events (e.g., suicide attempts), suggesting the drug capacity of crossing the 
blood brain barrier, supported by the shrinkage of brain metastases (Bendell, Rodon et al. 2012, 
Baselga, Im et al. 2017, Martin, Chan et al. 2017). Buparlisib combined with fulvestrant is 
being tested in breast cancer (Di Leo, Johnston et al. 2018). 
 Isoform-specific PI3K inhibitors have been developed to target cancers specifically 
dependent on one PI3K isoforms. PI3Kα inhibitors specifically inhibit the p110α subunit, to 
counter-balance activating mutations of PIK3CA. Currently, no PI3Kα inhibitors are approved 
but several are in clinical trials (e.g., alpelisib, taselisib, TAK-117, ASN003). Compared to 
pan-PI3K inhibitors, these inhibitors have a favorable toxicity profile, good efficacy on 
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PIK3CA mutant tumors, and less off-target effects (Janku, Yap et al. 2018). In breast cancer, 
they are being tested in combination with standard of care hormone treatment (e.g., alpelisib 
combined to fulvestrant or letrozole) (Juric, Rodon et al. 2018). Of note, other isoform-specific 
PI3K inhibitors are being investigated: PI3Kβ specific inhibitors (e.g., GSK2636771, 
AZD8186, SAR260301), particularly effective in PTEN mutant tumors; PI3Kγ, a subunit 
mainly expressed in leukocyte, with one inhibitor in phase I (IPI-549); and against PI3Kδ-
subunit (e.g., duvelisib, AMG319), important mediator of B cell receptor signaling, beside the 
approved idelalisib (Furman, Sharman et al. 2014). 
 Another strategy consists in simultaneous blockade of pan-PI3K and mTOR. They have 
similar toxicity profiles than pan-PI3K inhibitors. Presently, no dual-PI3K/mTOR inhibitors 
have been approved but several are being tested in clinical trials (e.g., LY3023414, PQR309). 
The lack of biomarkers remains a major challenge to better stratify patients in clinical trials 
(Janku, Yap et al. 2018).  
3.7.4 Mechanisms of resistance to PI3K inhibition 
The importance of PI3K in cancer, and accessibility of druggable targets triggered studies and 
inhibitors design to interfere with this pathway in cancer (Leroy, Amante et al. 2014). However, 
results from clinical trials show limited efficacy due to resistance mechanisms. 
Resistance to PI3K inhibition can be driven by non-genetic mechanisms. For example, 
blockade of mTORC1 abrogates the p70 ribosomal protein S6 kinase 1 (S6K1) mediated 
negative feedback loop, upregulates the insulin receptor substrate 1 (IRS-1), and results in the 
reactivation of the PI3K pathway. These observations paved the way for the development of 
dual PI3K/mTOR inhibitors (O'Reilly, Rojo et al. 2006, Thorpe, Yuzugullu et al. 2015). This 
dual-inhibition is short-circuited in TNBC by the parallel activation of the JAK2/STAT5 
signaling pathway (Britschgi, Andraos et al. 2012), or by the rapid increase of expression of 
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RTK genes such as HER3, EGFR, the insulin receptor (INSR) and insulin like growth factor 
receptor 1 (IGFR1), driven by the forkhead transcription factors of the O subgroup (FOXO) 
activity (Chandarlapaty, Sawai et al. 2011, Chakrabarty, Sanchez et al. 2012, Muranen, Selfors 
et al. 2012).  
Acquired resistances to PI3K inhibition also develops. The persistent mTORC1 activity 
upon BYL719 (alpelisib) inhibition, drove insensitivity of these cells in PIK3CA mutant breast 
cancers. Sensitivity could be restored by simultaneous mTORC1 blockade using RAD001 
(everolimus) (Elkabets, Vora et al. 2013). Further, mTORC1 can be activated via PI3K-
independent signaling, seen with the serine-threonine kinase PIM1 in luminal A/B and HER2+ 
breast cancers. Increased PIM1 expression correlates with BYL719 resistance, and has been 
confirmed in 50% of patient biopsies at time of progression (Le, Antony et al. 2016). In breast 
cancer, MYC copy number and/or c-Myc expression is elevated and drive resistance to 
PI3K/mTOR inhibition (Ilic, Utermark et al. 2011). Strategies targeting the bromodomain and 
extra-terminal domain (BET) BRD4 proteins antagonize these resistances by suppressing the 
super-enhancer-associated genes such as MYC (Liu, Radisky et al. 2012). Also, compensatory 
mechanisms could be blocked by use of the BET inhibitor JQ1, in PIK3CA or PTEN mutant 
cell lines in which PI3K pathway was reactivated by RTKs (Stratikopoulos, Dendy et al. 2015). 
The MAPK pathway is crucial in these compensation mechanisms to PI3K inhibition, notably 
upon mTORC1 inhibition (Carracedo, Ma et al. 2008, Leroy, Amante et al. 2014, Ramos and 
Bentires-Alj 2015). 
 Furthermore, a cancer is constituted of heterogeneous populations, formed of different 
clones, which respond differently to treatments. Heterogeneity can be seen in between patients; 
within patient tumor; and within patient sites such as primary tumor and metastatic lesions 
(Heppner 1984, McGranahan, Favero et al. 2015, Dagogo-Jack and Shaw 2018). For example, 
brain metastases have been shown to contain more PI3K activating mutations than primary 
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tumor, predicting differential site responses to a PI3K inhibition (Brastianos, Carter et al. 
2015). 
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4 | RATIONALE OF THE WORK 
Breast cancer is the most frequent cancer and the leading cause of death among women 
worldwide. Several signaling pathways promote aberrant cancer cell proliferation. Among 
them, the PI3K pathway is activated in 70% of breast cancers, highlighting the importance of 
developing strategies to inhibit this pathway. However, PI3K inhibition has shown 
disappointing results in clinical trials, predominantly due to the occurrence of resistance. 
Frequently, these mechanisms of resistance are RTK driven, which activate compensatory 
pathways. 
 Signaling pathways are composed of several proteins and complexes in which 
phosphorylation of tyrosine residues is crucial. Abnormal tyrosine phosphorylation causes a 
wide range of diseases. The reversible phosphorylation of these tyrosine residues is governed 
by PTKs and PTPs. Whereas PTKs were considered as major drivers, PTPs were only 
considered as attenuating factors. Previous work in our lab demonstrated that the tyrosine 
phosphatase SHP2 promotes breast cancer maintenance and progression. Suppression of SHP2 
decreases tumor growth, eradicates breast-tumor-initiating cells in xenograft models and 
reduces metastasis. Furthermore, SHP2 is important for RTK signaling where it facilitates 
activation of downstream pathways. 
We asked whether SHP2 inhibition could improve PI3K inhibition by addressing the 
following points: 
i. What are the effects of pan-PI3K and SHP2 blockade as single- or dual-inhibition on 
breast cancer progression?   
ii. What is the molecular mechanism of action of PI3K/SHP2 dual-inhibition in breast 
cancer? 
iii. What are the effects of PI3K/SHP2 dual-inhibition on metastases?  
Results 
- 36 - 
 
5 | RESULTS 
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5.1 Summary 
The PI3K pathway is hyperactivated in 70% of breast cancers and numerous inhibitors of this 
pathway are in clinical trials. Resistance to PI3K inhibition is often driven by activation of 
receptor tyrosine kinases (RTKs). Given that the protein tyrosine-phosphatase SHP2, encoded 
by the proto-oncogene PTPN11, activates oncogenic pathways downstream of most RTKs, we 
assessed the effect of co-targeting both PI3K and SHP2 in preclinical models of metastatic 
triple negative breast cancer (TNBC) a highly aggressive subtype that lacks targeted therapy. 
Beside the beneficial effects of SHP2 single inhibition, dual PI3K/SHP2 inhibition induced 
apoptosis, decreased primary tumor growth synergistically, blocked the formation of lung 
metastases, and increased overall survival in both neoadjuvant and adjuvant settings. 
Mechanistically, SHP2 inhibition resulted in the activation of PI3K signaling via PDGFRβ and 
sensitization of TNBC cells to inhibition of this pathway. The data provide a rationale for co-
targeting SHP2 and PI3K in metastatic TNBC. 
5.2 Introduction 
Breast cancer is the leading cause of cancer death among females, with 1.7 million new cases 
globally and 600,000 deaths annually (Parks, Derks et al. 2018). A third of breast cancers 
progress to metastasis (Early Breast Cancer Trialists' Collaborative 2005), the cause of death 
of most breast cancer patients (Massague and Obenauf 2016). Thus, anti-cancer target 
identification, drug development and testing should focus on metastatic cells before and/or 
after they have spread and proliferated in distant organs. This is key to the improvement of 
current therapies. 
The phosphatidylinositol 3-kinase (PI3K) signaling axis is essential for cell 
proliferation, cell-cycle progression, motility and apoptosis (Fruman, Chiu et al. 2017). 
Downstream of receptor tyrosine kinases (RTK) and G protein-coupled receptors (GPCR), 
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class I PI3Ks phosphorylate phosphatidylinositol-4,5-bisphosphate, generating 
phosphatidylinositol-3,4,5-triphosphate, and lead to the activation of numerous kinases such as 
PDK1 (phosphoinositide-dependent kinase 1), AKT (also called protein kinase B), and p70 
ribosomal protein S6 kinase (S6K) (Manning and Toker 2017). 
The PI3K pathway is among the most frequent pathways activated in human cancer, 
and is hyperactivated in 70% of breast cancers (Saal, Holm et al. 2005, Stemke-Hale, Gonzalez-
Angulo et al. 2008). Different classes of inhibitors targeting several key effectors (e.g., PI3K, 
AKT, mTOR) have been developed over the last two decades and 17 compounds are currently 
in clinical trials on solid tumors (Janku 2017). Unfortunately, the efficacy of these inhibitors is 
limited by intrinsic and adaptive (non-genetic) mechanisms: increased transcription of RTK 
genes, feedback loop disruption, and activation of parallel pathways (Ramos and Bentires-Alj 
2015, Fruman, Chiu et al. 2017). These observations pinpoint the crucial need for refined drug 
combinations to overcome resistance mechanisms. 
Downstream of various active RTKs, Src-homology 2 domain-containing phosphatase 
(SHP2), a ubiquitously expressed protein-tyrosine phosphatase (PTP), transduces mitogenic, 
survival, cell-fate and/or migratory signals (Bentires-Alj, Gil et al. 2006, Aceto, Sausgruber et 
al. 2012, Lan, Holland et al. 2015, Sausgruber, Coissieux et al. 2015). SHP2 is fundamental to 
the activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-related 
kinase (ERK) pathway (Chan and Feng 2007). Germline-activating mutations of SHP2 cause 
Noonan syndrome (Tartaglia and Gelb 2005), and somatic gain of function mutations cause 
several hematological malignancies (Tartaglia, Niemeyer et al. 2003). While PTPN11 is rarely 
mutated in solid tumors, SHP2 is activated downstream of several oncogenic signals (Bentires-
Alj, Paez et al. 2004, Tsutsumi, Masoudi et al. 2013, Bunda, Burrell et al. 2015). Notably, small 
hairpin knockdown of SHP2 decreases breast tumor growth and progression (Aceto, 
Sausgruber et al. 2012, Sausgruber, Coissieux et al. 2015, Matalkah, Martin et al. 2016). A 
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potent orally active allosteric inhibitor of SHP2 has been reported recently (Chen, LaMarche 
et al. 2016) but the effect of pharmacological inhibition of SHP2 on breast cancer metastases 
and overall survival remains ill-defined. Of note, SHP2 inhibition is currently in a phase I trial 
focusing on advanced solid tumors (NCT03114319). 
Given that RTKs often blunt the response to PI3K inhibition and that SHP2 transduces 
oncogenic signaling downstream of most RTKs, we asked whether co-targeting these pathways 
would be more effective than single agents in preclinical models of metastatic TNBC. Using 
in vitro models as well as different in vivo treatment settings, including neoadjuvant and 
adjuvant treatments in immunocompetent and immunodeficient models, we compared the 
efficacy of PI3K and SHP2 alone or as dual-inhibitors, measuring their impact on primary 
tumor and metastatic growth, as well as on overall survival. Here we provide data that challenge 
the notions that: a) primary tumors and metastases have the same dependencies, and b) that the 
quantification of primary tumor response to therapy is a reliable metric for assessing anti-
cancer drug efficacy. We also reveal differences in lung- and liver metastases dependency.  We 
provide evidence that PI3K/SHP2 dual-inhibition is necessary and sufficient to overcome lung 
metastases growth and prolongs survival in preclinical models of metastatic TNBC. 
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5.3 Results 
5.3.1 PI3K/SHP2 dual-inhibition decreases cell number, reduces primary 
tumor growth and increases overall survival in TNBC models. 
We assessed the effects of the pan-PI3K inhibitor CLR457 combined with SHP099, an SHP2 
allosteric inhibitor (Chen, LaMarche et al. 2016) on the 4T1 metastatic mouse mammary 
carcinoma cell line and a representative panel of human breast cancer cell lines. 4T1 cells and 
all the human TNBC lines but MDA-MB-231 were more sensitive to dual- than to single 
inhibition, with three lines out of five showing a synergistic effect and two an additive effect 
(Fig 5-1 A-E). While PI3Ki inhibition alone does not induce cell apoptosis (Chen, Hsiao et al. 
2017, Zwang, Jonas et al. 2017), SHP2i induced apoptosis dramatically (Fig EV1A), and 
PI3K/SHP2 dual-inhibition induced it further (Fig 5-1F).  
To elucidate the effect of PI3K/SHP2 dual-inhibition in vivo, we used the 4T1 
syngeneic mouse model of metastatic breast cancer in a neoadjuvant setting (Fig 5-1G). PI3Ki 
had no effect on tumor growth, whereas SHP2i decreased average tumor volume by half; dual-
inhibition decreased it further in a synergistic manner (Fig 5-1H, Fig EV1B). Quantification of 
cleaved-Caspase 3 in tumors after treatment indicated increased apoptosis upon SHP2i and 
PI3K/SHP2 dual-inhibition (Fig EV1C). 
After tumor resection, the mice were treated for 5 days in a second round of inhibition 
and monitored until signs of distress appeared. Only PI3K/SHP2 dual-inhibition enhanced 
overall survival, with a median survival of 41 days; mice after all other treatments had a median 
survival of 20-24 days (Fig 5-1I). While the effects on primary tumor growth varied, overall 
survival was also prolonged by PI3K/SHP2 dual-inhibition in mice transplanted with MDA-
MB-436 or MDA-MB-468 cell lines (Fig EV1D-E). Analysis of lungs revealed the presence 
of larger metastases in the PI3K-treated group than in the control, similar to our previous 
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observation with TNBC models (Fig EV1F) (Britschgi, Andraos et al. 2012). In contrast, mice 
after SHP2 single inhibition or combined inhibitors had few or no lung metastases (Fig EV1F). 
The reduction in lung metastases by SHP2 single inhibition in the absence of increased overall 
survival may be due to an overshoot of metastasis after cessation of treatment, a phenomenon 
that is prevented by combined PI3K/SHP2 inhibition. 
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Figure 5-1 │ PI3K/SHP2 inhibition reduces cell number and primary tumor volume, and 
prolongs animal survival. 
A   Representative images of 4T1 cells treated with CLR457 (PI3Ki) and SHP099 
(SHP2i) at the indicated concentrations for 72 h. Each condition is shown in triplicate 
(horizontal).  
B, C, D  Bar graph representing cell number of 4T1 cells treated with CLR457 (PI3Ki) 
or SHP099 (SHP2i) at the indicated concentrations for 72 h. Data shown are mean cell numbers 
±STDEV (n=3, **P≤0.01; ***P≤0.001; ****P≤0.0001, One-way ANOVA test).  
E   Bar graph of the cell numbers of breast cancer lines treated with CLR457 
(PI3Ki, 2.5 µM) and/or SHP099 (SHP2i, 5 µM) for 72 h. Dual-inhibition is compared to single 
inhibition in terms of additive or synergistic (ADD: Additive; SYN: Synergistic). Data shown 
are mean cell numbers ±STDEV (n=3, *P≤0.05, One-way ANOVA test).  
F   Representative FACS plots of annexin V (AV) / propidium iodide (PI) apoptosis 
analysis of 4T1 cells treated with CLR457 and SHP099 for 3 days (top panel). Fresh inhibitors 
were added after 48 h. Quantification is given as a bar plot (bottom panel). Data shown are 
means ±STDEV (n=3, *P≤0.05; ***P≤0.001, Two-way ANOVA test).  
G   Design of treatments in the neo-adjuvant setting. One week after tumor cell 
injection, treatments were applied for 14 days (d=days). After tumor removal and 5 days of 
recovery, a second round of treatment of 5 days followed. The overall survival of the animals 
was recorded.  
H   Tumor volumes of 4T1-tumor-bearing mice treated with Vehicle, CLR457 
and/or SHP099. Data shown are mean tumor volumes ±SEM (n=6-8, *P≤0.05; ***P≤0.001; 
****P≤0.0001, One-way ANOVA test).  
I   Overall survival of 4T1-tumor-bearing mice treated as indicated. An event was 
scored at the appearance of any sign of distress (n=6-8, **P≤0.0012, Log-rank test). 
 
5.3.2 SHP2 inhibition sensitizes cells to PI3K inhibition. 
Immunohistochemistry revealed very low p-AKT levels in 4T1 control tumors (Fig 5-1H, Fig 
5-2A, top-panel), with less than 1.6% positive pixel counts in quantified areas, but p-AKT 
increased significantly (7%) upon prolonged single SHP2i treatment. This increase in p-AKT 
was blocked by dual-inhibition, which suggested a specific mechanism for the improved 
response to dual-inhibition on tumor progression (Fig 5-1H). SHP2i blocked p-ERK after 4 
days of treatment (Fig EV2A) but cells that survived after 14 days of treatment displayed a 
level of p-ERK similar to the control and to PI3Ki-treated samples (Fig 5-2A, bottom-panel). 
Thus, both the PI3K and ERK pathways were reactivated in cells that survived SHP2i, an effect 
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that was prevented by PI3K/SHP2 dual-inhibition. Furthermore, treatment for 4 days with 
SHP2i alone had no effect on p-AKT and PI3Ki alone had no effect on p-ERK (Fig EV2A). 
To assess the effects of PI3K/SHP2 dual-inhibition on the transcriptome, we performed 
a RNA sequencing of tumors 3 hours after the above dual-inhibition treatments (Fig 5-2B). 
After CLR457 treatment, 266 genes were up- or downregulated, 487 genes after SHP099 
inhibition, and 1523 after dual-inhibition, consistent with the effects of these treatments on 
tumor growth (Fig 5-1H, Fig EV2B). Overall gene expression changes were similar within 
groups, with steady clustering in a PCA plot (Fig 5-2C).  
Using the cBioPortal for cancer genomics and the breast cancer METABRIC dataset, 
network analysis of the 35 most-upregulated genes in the SHP2 inhibition group compared to 
the vehicle group (Fig 5-2D, Fig EV3A) showed convergence to the Src Homology 2 Domain-
Containing 1 (SHC1), PIK3CA and AKT3 (Fig 5-2E). SHC1 is an adaptor protein that 
facilitates interactions between RTKs and a large number of downstream proteins, including 
the PI3K subunit p85 that forms an activating complex with p110 (Heldin 2013). 
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Figure 5-2 │ SHP2 blockade reactivates the PI3K pathway. 
A Representative images of the immunohistochemistry staining of 4T1 tumors from mice 
treated for 14 days with Vehicle, CLR457 and/or SHP099. Bar graph shows the quantification 
of p-AKT (Ser473) (top panel) and p-ERK (Thr202/Tyr204) staining (bottom panel). Tumors 
were collected as described in Fig 1G. Scale bar 100 µm. Data are means ±STDEV (n=7-8, 
**P≤0.01; ***P≤0.001; ****P≤0.0001, One-way ANOVA test).  
B  Venn diagram of transcriptomic variation (up- and down-regulation) in 4T1 tumors 
from mice treated with CLR457 (PI3Ki) and/or SHP099 (SHP2i) compared to the control 
group. Data shown are individual values (n=4-5, logFC>1 or <-1, FDR<0.05).  
C  PCA plot of RNA-seq data from 4T1 tumors of mice treated with Vehicle (Vhc), 
CLR457 and/or SHP099.  
D  Heat map of the top 35 upregulated genes in 4T1 tumors of mice treated with Vehicle 
or SHP099. Data shown are individual values (n=4-5, logFC>1.5, FDR<0.01).  
E  Network generated using cBioportal showing the top 35 genes described in Fig 2D and 
their most frequently altered neighboring genes (filtered, 21%) in the breast cancer 
METABRIC dataset (Blue: control change of state; brown: in complex). 
 
5.3.3 SHP2 inhibition enhances PDGFRα,β signaling. 
We next quantified the total tyrosyl-phosphorylation of 39 RTKs in tumor protein lysates from 
SHP099-treated tumors (Fig 5-1H). Several RTKs were highly phosphorylated after SHP2 
inhibition compared to the control (Fig 5-3A, Fig EV3B). We subsequently focused on platelet-
derived growth factor receptor (PDGFR) because increased activity of PDGFR signaling has 
been shown to promote tumor growth, invasion and lung metastasis (Gehmert, Gehmert et al. 
2010, Liu, Liao et al. 2011), and PDGFR blockade sensitizes cells to chemotherapeutic agents 
(Meng, Speyer et al. 2015). Besides the importance of this RTK for tumor progression and 
metastasis, SHC1 is able to bind autophosphorylation sites of PDGFRs (Heldin, Ostman et al. 
1998).  
No transcriptomic variation was observed between groups of PDGF receptors and 
ligands (Fig 5-3B, Fig EV3A). Ligand stimulation of PDGFRα and PDGFRβ has been shown 
to increase phosphorylation of Y849 and Y857, respectively (Baxter, Secrist et al. 1998). 
Stimulation of 4T1 cells with the PDGF-BB ligand also increased Y849 and Y857 
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phosphorylation (Fig 5-3C). Phosphorylation of these sites was found to be enhanced in 
primary tumors and further enhanced in lung metastases. This correlated with increased p-ERK 
and p-AKT, suggesting PDGFR-evoked activation of these pathways in lung metastasis (Fig 
5-3D, Fig EV4A-B). Similar to its effects on primary tumors, SHP2 inhibition decreased p-
ERK and increased p-AKT, whilst PI3K inhibition decreased SHP2i-evoked AKT 
phosphorylation. SHP2 blockade resulted in increased phosphorylation on SHC1 Y317, which 
has been shown to include docking sites for other PTB- and SH2- containing proteins and to 
lead to activation of several pathways, including PI3K/AKT (Ahn, Sabourin et al. 2017). SHP2i 
also increased PDGFRβ Y751 phosphorylation, the docking site for the regulatory subunit of 
PI3K p85 (Fig 5-3C) (Kazlauskas and Cooper 1990). These observations suggest a mechanism 
by which SHP2i activates the PI3K/AKT pathway. 
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Figure 5-3 │ Inhibition by SHP2 activates PDGFRα,β signaling and the PI3K pathway. 
A  Receptor Tyrosine Kinase (RTK) array from 4T1 tumors of mice treated with Vehicle 
or SHP099 and bar plots (right) of PDGFRβ phosphorylation. Data shown are dot quantification 
by pixel density from RTK-array scans.  
B  Heat map of PDGF-family-related genes in 4T1 tumors of mice treated with Vehicle, 
CLR457 and/or SHP099. Data shown are individual values (n=4-5, logFC>4, FDR<0.01).  
C  Immunoblots of lysates from 4T1 cells that were grown as monolayers and treated with 
PI3Ki (CLR457, 300 nM) and/or SHP2i (SHP099, 5 µM) and stimulated with PDGF-BB 500 
ng/mL for 20 h.  
D  Representative IHC images of 4T1 tumors from mice treated with Vehicle, CLR457 
and/or SHP099. Bar graph showing pixel count from Halo software quantifying PDGF 
Receptor α (Y849)/PDGF Receptor β (Y857) staining. Tumors were collected as described in 
Fig 1G. Scale bar 100 µm. Data shown are means ±STDEV (n=6-7, *P≤0.05; **P≤0.01; One-
way ANOVA test).  
 
5.3.4 Single PI3K or SHP2 inhibition or dual PI3K/SHP2 inhibition decreases 
lung metastases in the adjuvant setting. 
We assessed the effects of PI3K and/or SHP2 inhibition in the adjuvant setting. 4T1 cells were 
injected into syngeneic animals and the primary tumors were removed 3 weeks later; animals 
were then treated as described in Fig 5-4A. After 9 days of treatment, we found numerous 
metastatic foci in lungs of control mice (an average penetrance of metastasis of 208 arbitrary 
units) (Fig 5-4B). Surprisingly, the penetrance of metastasis was dramatically lower (15 times) 
in all treatment groups. Thus, single treatments appear to be as effective as PI3K/SHP2 dual-
inhibition in decreasing lung metastases in the adjuvant setting. Both CLR457 and SHP099 
potently blocked p-AKT and p-ERK in metastases, respectively (Fig 5-4C).  
To test whether the reduction in lung metastases translates to an increase in overall 
survival, we monitored animals after the adjuvant treatment. All inhibitor treatments extended 
animal survival, whether treatment was interrupted after 14 days (median survival: vehicle 15 
days, treated groups 19-23 days) or was continuous (median survival: vehicle 15 days, treated 
groups 19-26 days) (Fig 5-4D, Fig EV4C). Similar results were found with a TNBC human 
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primary-derived xenograft, where animal survival was prolonged in all treated groups in the 
adjuvant setting (Fig EV4D). In contrast, only PI3K/SHP2 inhibition enhanced overall survival 
in the neoadjuvant setting (Fig 5-1I).  
We assessed the cause of death of mice from the different treatment groups in the 
adjuvant setting and found lung macro-metastases only in the CLR457 and SHP099 groups. 
Indeed, the PI3K/SHP2 dual-inhibition group had rare lung metastases despite signs of distress 
(Fig 5-4E). Because 4T1 cells are highly invasive and can colonize various sites (Pulaski and 
Ostrand-Rosenberg 1998, Lelekakis, Moseley et al. 1999), we also analyzed livers from these 
animals. Metastatic liver lesions in the PI3K/SHP2 dual-inhibition group were more frequent 
than in the other groups (Fig 5-4 F-G), in contrast to the absence of lung macro-metastases. 
The data suggest that survival and growth of metastases within the lung niche depends on PI3K 
and SHP2. Within the liver niche, other factors may promote survival and growth of metastases 
despite dual PI3K/SHP2 inhibition. 
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Figure 5-4 │ PI3K and/or SHP2 blockade in the adjuvant setting decreases lung 
metastases and improves animal survival. 
A  Experimental design of the adjuvant treatment. Tumors were resected 3 weeks after 
cancer cell injection. After 5 days of recovery, treatments were applied for 9 days. Lungs were 
collected continuously until signs of distress developed or for 14 days during which mice were 
monitored for signs of distress.  
B  Representative images of H&E staining of lungs from mice treated as indicated for 9 
days, together with the associated penetrance of metastasis. Scale bar 100 µm.  
C  Representative images of H&E, p-ERK (Thr202/Tyr204) and p-AKT (S473) staining 
of lungs from 4T1-tumor-bearing mice treated as indicated (left). Bar graphs showing 
quantification of staining (bottom). Data shown are means ±STDEV (n=4-5, *P≤0.05 
**P≤0.01; ****P≤0.0001, One-way ANOVA test). 
D  Kaplan-Meier survival curves of 4T1 tumor-bearing mice treated in the adjuvant setting 
as indicated. An event was scored when a mouse showed any sign of distress (n=14-16, 
**P≤0.0012, Log-rank test).  
E  Bar graphs of the percentage of lungs with macro-metastases from animals treated in 
the adjuvant setting (Fig 5-4D) as indicated. Lungs were collected at necropsy. Data shown are 
total counts (n=12-13).  
F  Bar graphs showing the mean densities of metastatic liver foci from animals treated in 
the adjuvant setting (Fig 5-4D) as indicated. Livers were collected at necropsy. Data shown are 
means ±STDEV (n=5-7, ***P≤0.001, One-way ANOVA test).  
G  Representative image from liver metastases at necropsy from animals treated in the 
adjuvant setting (Fig 5-4D). Black line delineates metastatic lesion. Scale bars 700 µm (left) 
and 100 µm (right). 
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5.4 Expanded view figures 
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Figure EV1 │ SHP2 single inhibition enhances apoptosis and PI3K/SHP2 dual-inhibition 
prolongs overall survival of TNBC-tumor-bearing mice. 
A FACS plot of the apoptosis analysis of 4T1 cells treated for 3 days with CLR457 (top 
panel) or SHP099 (bottom panel) at the indicated concentrations. Fresh inhibitors were added 
after 48 h. Quantification is shown as bar plots.  
B Bar plot of tumor volumes of 4T1-tumor-bearing mice after 14 days of treatment as 
indicated. Data shown are mean tumor volumes ±SEM (n=6-8, *P≤0.05; ***P≤0.001; 
****P≤0.0001, One-way ANOVA test).  
C Representative images of cleaved-Caspase 3 IHC staining of lung metastases from 4T1-
tumor-bearing mice treated in the adjuvant setting for 4 days as indicated (left). Bar graph of 
the quantification using the pixel count algorithm performed with Halo software (right). Scale 
bar 100 µm. Data shown are means ±STDEV (n=3, **P≤0.01; ***P≤0.001, One-way ANOVA 
test).  
D, E  Tumor volume growth and Kaplan-Meier overall survival of MDA-MB-436 and MDA-
MB-468 tumor-bearing mice treated as given. Data shown are mean tumor volumes ±SEM 
(n=4-6, *P≤0.05; **P≤0.01, One-way ANOVA test).  
F Representative images of H&E-stained lungs from 4T1-tumor-bearing mice treated as 
described in Fig. 1G. Black lines delineate metastases. Scale bar 100 µm (left panel). Plot of 
the percentages of lungs with metastases from Vehicle-, CLR457-, SHP099-, and 
CLR457+SHP099-treated groups. Data shown are means ±STDEV (n=7-8, ***P≤0.001; 
****P≤0.0001, One-way ANOVA test) (middle panel). Bar graph of the quantification of 
metastatic areas in Vehicle- and CLR457-treated groups (the data for SHP099 and 
CLR457+SHP099 groups are not shown because no metastatic foci were detected). Small 0-
0.1; Medium 0.1-0.5; Large 0.5 mm2. Data shown are means ±STDEV (n=7-8, 
****P≤0.0001, t-test) (right panel). 
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Figure EV2 │ Single inhibition of PI3K or SHP2 in vivo blocks activation of the PI3K and 
the MAPK pathways, respectively, and transcriptomic changes are wider following 
PI3K/SHP2 dual-inhibition than single inhibitions. 
A Representative images of p-AKT (Ser473) (left panel) and p-ERK (Thr202/Tyr204) 
(middle panel) IHC-stained 4T1 tumors from mice treated for 4 days as indicated. Bar graphs 
show quantification using the pixel count algorithm performed with Halo software (right 
panels). Tumors were collected as described in Fig. 1G. Scale bar 100 µm. Data shown are 
means ±STDEV (n=4-5, **P≤0.01; ***P≤0.001; ****P≤0.0001, One-way ANOVA test).  
B Volcano plots showing transcriptomic variation in 4T1 tumors from mice treated as 
indicated. Data shown are individual values (n=4-5, logFC>1, FDR<0.05). 
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Figure EV3 │ Increased tyrosyl-phosphorylation of several RTKs upon SHP2 inhibition 
without effects on the transcriptome of the PDGF-related gene family. 
A Volcano plots of transcriptomic variation of the “PDGF-related gene family” and the 
“top 35 upregulated genes” in 4T1 tumors from mice treated with SHP099. Data shown are 
individual values (n=4-5, logFC>1.5, FDR<0.01). 
B Bar graph of the quantification of the 10 most-enriched phospho-tyrosyl-RTKs in 4T1 
tumors from mice treated as indicated. Data shown are dot quantification by pixel density from 
RTK-array scans.  
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Figure EV4 │ PI3K/SHP2 dual-inhibition in the adjuvant setting prolongs overall 
survival. 
A Representative images of PDGF Receptor α (Y849)/PDGF Receptor β (Y857) IHC 
stained lungs from 4T1-tumor-bearing mice treated as indicated (left). Bar graph shows 
quantification using the pixel count algorithm performed with Halo software (right). Scale bar 
100 µm. Data shown are means ±STDEV (n=6-7, *P≤0.05, One-way ANOVA test).  
B Bar plots of the percentages of phosphorylated proteins in primary tumors and lung 
metastases. Data shown are means ±STDEV (n=6-8, **P≤0.01; ****P≤0.0001, One-way 
ANOVA test). 
C Kaplan-Meier survival curves of 4T1-tumor-bearing mice treated continuously in the 
adjuvant setting as indicated. An event was scored when a mouse showed any sign of distress 
(n=10-16, **P≤0.0001, Log-rank test).  
D Kaplan-Meier survival curves of HBRX2353 primary-derived xenograft-tumor-bearing 
mice treated in the adjuvant setting as shown. An event was scored when a mouse showed any 
sign of distress (n=4-5, *P= 0.0585, Log-rank test).  
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5.5 Discussion 
Targeted therapies in combination with chemo- or hormone therapy have improved the survival 
of patients at different stages of breast cancer. Approved mechanism-based therapies for breast 
cancer such as Trastuzumab, Everolimus, Olaparib, Palbociclib, Ribociclib, and Abemaciclib 
target specific cancer dependencies with consequently fewer side effects. Extensive work on 
protein 3D structures and detailed inhibitor design have made protein targeting even more 
specific and effective (Gampenrieder, Rinnerthaler et al. 2013, Garcia Fortanet, Chen et al. 
2016). Despite initial successes, these strategies are hindered by the development of resistance, 
leading to cancer cell insensitivity and restricted therapeutic solutions (Groenendijk and 
Bernards 2014, Leroy, Amante et al. 2014, Ramos and Bentires-Alj 2015, Dardaei, Wang et al. 
2018, Mainardi, Mulero-Sanchez et al. 2018). However, it is anticipated that combining 
targeted therapies together or with chemotherapy will potentiate the initial inhibition, overcome 
resistance, and improve patient outcome. In the present study, we found that a dual-inhibition 
using a pan-PI3K- and an allosteric SHP2-inhibitor significantly improves overall survival of 
mice with metastatic TNBC. 
We compared the effects of PI3K and/or SHP2 inhibition in the neoadjuvant and 
adjuvant settings by assessing drug response and overall survival of the animals. Neoadjuvant 
treatment with dual PI3K and SHP2 inhibition synergistically decreased primary tumor 
volume, led to complete tumor regression in almost all animals, and improved overall survival. 
While SHP2 but not PI3K inhibition alone decreased primary tumor volume, neither of these 
single treatments improved overall survival. Protein and transcriptome analyses revealed PI3K 
pathway activation upon SHP2 blockade in a PDGFR-dependent manner, which was blunted 
by combined inhibition of PI3K and SHP2.  
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In contrast, while PI3K inhibition alone had no effect on primary tumor growth, 
resulting in fact in larger metastases than the control in the neoadjuvant setting, it did decrease 
metastases and improve overall survival in the adjuvant situation. While, SHP2 inhibition 
decreased primary tumors and lung metastases but did not affect overall survival in the 
neoadjuvant treatment, it did decrease lung metastases and increase overall survival in the 
adjuvant setting. Combined PI3K and SHP2 inhibition decreased lung metastases and 
improved overall survival in both the neoadjuvant and adjuvant settings. Thus there appears to 
be differential sensitivity of cancer cells to targeted therapy at the primary site and in the lungs 
and, therefore, using primary tumor shrinkage alone as a measure of drug efficacy can be 
misleading. We have shown previously that anti-CCL2 or JAK2 or IL-8 inhibition have no 
effect on primary tumor growth but decrease lung metastases and increase overall survival 
(Britschgi, Andraos et al. 2012, Bonapace, Coissieux et al. 2014). Altogether, these findings 
stress the need for thorough evaluation of drug efficacy not only in vitro and on primary tumor 
growth but also on metastases and overall survival.  
Our observation that all mice treated with PI3K and/or SHP2 inhibitors in the adjuvant 
setting show similar improvement of overall survival may suggest that a single agent is 
sufficient. However, assessment of lungs from the different groups showed that mice treated 
with PI3K or SHP2 inhibitors have large metastases, while metastases were rare in mice treated 
with both agents. Further analysis revealed three times more liver metastases in mice after dual-
inhibitor as against single-inhibitor treatment. These data raise the possibility that metastases 
developing in the lung niche are sensitive to PI3K and to SHP2 inhibition, whereas resistance 
to this treatment develops in metastatic cells within the liver niche.  
The observation that pan-PI3K inhibition in the neoadjuvant setting increases lung 
metastases in TNBC calls for caution when using such agents in the presence of the primary 
tumor. We have reported similar results using a dual PI3K/mTOR inhibitor (Britschgi, Andraos 
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et al. 2012). A pan-PI3K inhibitor shows some efficacy as a single agent in the adjuvant setting 
but mice still succumb to lung metastases. Our data provide a rationale for using pan-PI3K in 
combination with SHP2 inhibition to treat metastatic TNBC in the adjuvant setting and support 
further testing of this possibility. 
5.6 Materials and methods 
Compounds 
CLR457 and SHP099 were obtained from Novartis (Basel, Switzerland and Cambridge, USA).  
Compounds were prepared as 10 mM stock solutions in DMSO and stored protected from light 
at –20°C. CLR457 (20 mg/kg) and SHP099 (100 mg/kg) were freshly formulated in 
methylcellulose/Tween-80 (0.5% / 0.5%) and administered to mice by oral gavage at 5 ml/kg.  
Animal Experiments 
All in vivo experiments were performed in accordance with the Swiss animal welfare ordinance 
and approved by the cantonal veterinary office of Basel Stadt. Female severe combined NOD-
scid IL2rγnull (NSG) and Balb/c animals were maintained in the Friedrich Miescher Institute 
for Biomedical Research and the University Department of Biomedicine animal facility in 
accordance with Swiss guidelines on animal experimentation. For orthotopic engraftment of 
cell lines, 0.3 x 106 4T1, 2 x 106 MDA-MB-436 and 2 x 106 MDA-MB-468 cells were 
suspended in 50 µL PBS and injected into mammary fat pad number 4 of 8-week-old mice. 
Tumor-bearing mice were randomized based on tumor volume prior to the initiation of 
treatment, which started when average tumor volume was at least 80 mm3. CLR457 was 
administered twice a day and SHP099 once daily. Tumors were measured every 3–4 days and 
tumor volumes calculated by the formula 0.5 x (larger diameter) x (smaller diameter)2. End 
point tumor sizes were analyzed for synergism using the formula AB/C < A/C x B/C, where C 
is tumor volume Vehicle, A is tumor volume compound 1, B is tumor volume compound 2, 
Results 
- 59 - 
 
and AB is tumor volume combination (Clarke 1997). For survival studies, day 0 corresponds 
to tumor removal, and animals were sacrificed as soon as they showed any sign of distress (e.g., 
breathing disorders, weight loss, or immobility). 
Cells, Cell Culture, Reagents and PDX Models 
SUM159 were propagated in Nutrient Mixture F-12 supplemented with 5% fetal calf serum, 
0.5 μg/ml hydrocortisone, and 10 μg/ml insulin (all from Sigma), 100 IU/ml penicillin, 100 
μg/ml streptomycin and 100 μg/ml Normocin (InvivoGen). Balb/c tumor-derived mammary 
cancer lines 4T1 were propagated in DMEM, with 10% fetal calf serum (all from Sigma), 100 
IU/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml Normocin (InvivoGen). MCF10A-
HER2/HER3 (Aceto, Sausgruber et al. 2012) were propagated in DMEM/F12 medium 
(Invitrogen) supplemented with 5% horse serum (Hyclone), 20 ng/ml EGF (Peprotech), 0.5 
μg/ml hydrocortisone, 100 ng/ml cholera toxin, and 10 μg/ml insulin (all from Sigma), 100 
IU/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml Normocin (InvivoGen). All other cell 
lines were obtained from and were cultured according to the protocols of the American Type 
Culture Collection. Profiling of human cell lines used highly-polymorphic short tandem repeat 
loci (STRs) (Microsynth). For treatment with inhibitor(s), cells were synchronized with 0.5% 
serum for 6 h to avoid masking effects of growth factors present under full-serum conditions. 
Culture medium containing the inhibitor(s) was then added and cells cultured for 20 h. PDX 
used for this study was described earlier (DeRose, Wang et al. 2011, Gao, Korn et al. 2015). 
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Cell Number Assay 
Cells were cultured overnight in 96-well plates at 1,000 cells/well before culture medium was 
added containing 0.5 % FCS (or HS) and the inhibitor(s) described above. The culture medium 
with inhibitor(s) was renewed 48 h after initial treatment and cells were fixed 24 h later. Cell 
fixation, staining and quantification were performed using the Sulforhodamine B colorimetric 
assay (Vichai and Kirtikara 2006). 
Immunoblotting and Phospho-RTK Arrays 
Cells were lysed with RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS) supplemented with 1x protease inhibitor cocktail (Complete 
Mini, Roche), 0.2 mM sodium orthovanadate, 20 mM sodium fluoride and 1 mM 
phenylmethylsulfonyl fluoride. Lysates from xenografts were prepared by lysing kryo-
homogenized tumor powder in RIPA buffer. Whole cell lysates (30-80 μg) were subjected to 
SDS-PAGE, transferred to PVDF membranes (Immobilon-P, Millipore) and blocked for 1 h at 
room temperature with 5% milk in PBS-0.1% Tween 20. Membranes were then incubated 
overnight with antibodies as indicated and exposed to secondary HRP-coupled anti-mouse or 
anti-rabbit antibodies at 1:7,500 for 2 h at room temperature. The following antibodies were 
used (from Cell Signaling unless stated otherwise): anti-pAKT (Ser473), anti-pERK1/2 
(Thr202/Tyr204), anti-pPDGFRα/β (Y849/Y857) anti-pPDGFRβ (Y751, Thermo Fisher), anti-
ERK2 (Santa Cruz), anti-pSHC1 (Y317), anti-PDGFRβ, anti-AKT, anti-SHC1. Phospho-RTK 
arrays on tumor lysates were performed using the Proteome Profiler Mouse Phospho-RTK 
Array Kit (R&D systems) according to the manufacture’s protocol. 
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Immunohistochemistry 
Tumors and livers were fixed in 10% NBF (neutral buffered formalin) for 24 h at 4°C, washed 
with 70% EtOH, and embedded in paraffin. Sections of 2.5 µm were cut and processed for 
hematoxylin and eosin (H&E) staining and immunohistochemistry. Prior to fixation, dissected 
lungs were inflated by injecting 5 mL of PBS through the trachea, then inflated with 5 mL of 
10% NBF and gently released into a tube filled with 10% NBF. Immunohistochemical staining 
was performed on formalin-fixed, paraffin-embedded tissue sections using a Bond-maX 
(Leica) fully automated system for anti-pPDGFRα/β (Y849/Y857), and a Discovery XT 
(Ventana) fully automated system for anti-pAKT (Ser473), anti-pERK1/2 (Thr202/Tyr204), 
anti-CD31 (Spring Biosciences) and anti-cleaved Caspase-3 (Asp175). Algorithms for 
quantitative analysis of immunostained positive areas and the areas of lung metastases were 
designed in Halo software that allowed assessment of the relative fractions of positive areas. 
To detect and measure angiogenesis, we performed the Aperio Microvessel Analysis 
Algorithm using CD31 staining. The “penetrance of metastasis” was calculated following the 
formula (∑ lung metastatic area/lung epithelium area)*(1/tumor volume)*1000. 
Apoptosis Assay 
Cells were synchronized with DMEM 0.5% serum overnight and then supplemented with 
medium containing inhibitor(s). Fresh inhibitors were added after 48 h and cells (floating and 
adherent) were collected 24 h later using trypsin-EDTA, resuspended in growth medium and 
counted. For Annexin V/propidium iodide staining, cells were washed twice with cold Cell 
Staining Buffer (Biolegend, #420201) and resuspended in Annexin V Binding Buffer 
(Biolegend, #422201) at a concentration of 1 x 106 cells/mL. Aliquots of Alexa Fluor 647 
Annexin V (5 µL) (Biolegend, #640911) and of Propidium iodide (10 µL) (Biolegend, 
#421301) were added to 100 µL of this suspension, which was then incubated for 15 min at 
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room temperature in the dark. After addition of 400 µl of Annexin V Binding Buffer to each 
tube, samples were analyzed by flow cytometry. 
Transcriptomic Analysis 
Total RNA was extracted from frozen tumors using the RNeasy Plus Mini Kit (Qiagen, 
#74136) and sample quality controlled on an Agilent 2100 Bioanalyzer system with the 
RNA6000 Nano kit (Agilent, #5067-1511). mRNA isolation was performed with the NEBNext 
Poly(A) mRNA magnetic isolation module (NEB, #E7490) and libraries prepared with the 
NEBNext Ultra II Directional RNA Library Prep kit (NEB, #E7765) according to the 
manufacturer’s recommendations. Samples were individually barcoded during library 
preparation using NEBNext Multiplex Oligos for Illumina Index Primers Sets 1 and 2 (NEB, 
#E7335 and #E7500). Library quality control was performed with the DNA1000 kit (Agilent, 
#5067-1504) on the Agilent 2100 Bioanalyzer system. Finally, libraries were sequenced on an 
Illumina NextSeq 500 and paired-end 75-bp reads generated. Adaptor trimming was performed 
using cutadapt (Martin 2011). Trimmed reads were aligned to the GRCm38 genome using the 
two-pass approach of STAR (Dobin, Davis et al. 2013). A median of 53 million reads (range 
44-60) were aligned per sample. qCount from QuasR (McCarthy, Chen et al. 2012) was then 
used to obtain counts at the gene level. Differential gene expression was performed using 
edgeR (McCarthy, Chen et al. 2012). A cutoff of log2 fold change > 1 and adjusted to P < 0.05 
(corrected by the Benjamini–Hochberg algorithm method) was applied to selected genes. 
Network analysis was performed on the cBioportal website using the breast cancer dataset 
METABRIC (http://www.cbioportal.org/). 
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Statistical Analysis 
In each of the studies presented, the results shown represent at least three independent 
experiments. Values are reported as means ± STDEV. Data were tested for normal distribution 
and ANOVAs tests were applied. GraphPad Prism 7.04 was used for Kaplan-Meier survival 
analysis and log rank Mantel-Cox tests were applied to test statistical significance (SAS), as 
well as for all other statistical tests (SAS). The P values < 0.05 were considered statistically 
significant. 
Data availability 
Transcriptomic data are available upon request. 
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5.7 Supplementary data figures: Targeting VEGFR-dependent liver metastases 
in addition to PI3K/SHP2 inhibition further improves animal survival. 
Liver metastases shorten the survival of patients with breast cancer and effective treatment 
strategies are lacking (Cardoso, Costa et al. 2017). VEGFR, NF-kappa B and MAPK have been 
shown to be active in 4T1 mammary carcinoma liver metastases (Chen, Zheng et al. 2017), and 
VEGFR inhibitors are being tested in the clinic for their effects on breast cancer liver 
metastases as single agent (Chien, Lee et al. 2013) or in combination (Xu, Stevens et al. 2014). 
Livers from mice in the PI3K/SHP2 dual-inhibition group treated in the adjuvant setting were 
found to have the highest microvessel density, and liver metastases were essentially growing 
around blood vessels (Fig EV5A). 
We next asked whether a triple therapy targeting PI3K/SHP2 as well as angiogenesis 
would decrease liver metastasis and further improve overall survival of the animals. Several 
multi-kinase inhibitors have been developed over the last decade, with different affinities for 
VEGFRs, PDGFRs, c-kit and FGFRs (Meadows and Hurwitz 2012). Since 4T1 lung 
metastases express PDGFRs (Fig EV4A) and liver metastases were shown to express VEGFRs 
(Chen, Zheng et al. 2017) but not PDGFRs (Fig EV5B), we selected the FDA-approved drug 
sunitinib to target VEGFRs, PDGFRs and c-kit. The effect of combining sunitinib with 
PI3K/SHP2 dual-inhibition was first tested on 4T1 cells in 3D culture. PI3K/SHP2 dual-
inhibition decreased cell viability as seen already with primary tumors (Fig 5-1H; Fig EV1B). 
PI3Ki had no effect on cell viability, compared to SHP2i (70%) and PI3K/SHP2 dual-inhibition 
(38%) (Fig EV5C). Sunitinib reduced cell viability to 25% and a triple combination of 
CLR457, SHP099 and sunitinib further reduced this to 7% (Fig. 5-5A). 
We then assessed the effects of the triple combination on animal survival. Mice in the 
adjuvant setting were treated for 16 days by alternating 4 days of treatment with a 2-day break 
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in order to limit drug toxicity. The sunitinib single-agent and the CLR457/SHP099 dual-
inhibition groups showed similar survival, with medians of 20 days and 23 days, respectively 
(Fig. 5-5B). The survival of the triple-combination group was significantly longer than any 
other group (29.5 days). Thus, a combination of PI3K, SHP2 and VEGFR/PDGFR inhibitors 
in the adjuvant setting had a higher therapeutic value than any other combination tested. 
 
Figure 5-5 │ A triple treatment with PI3K, SHP2 and VEGFR/PDGFR inhibitors further 
improves overall survival. 
A Bar graphs of cell viability of 3D cultures treated as indicated for 5 days; the treatment 
was refreshed every 2 days (left panel). Representative images of 3D cultures from each 
condition (right panel). Scale bar 100 µm. Data shown are means ±STDEV (n=4, 
****P≤0.0001, One-way ANOVA test).  
B Kaplan-Meier survival curves of 4T1-tumor-bearing mice treated in the adjuvant setting 
as shown. An event was scored when a mouse showed any sign of distress (n=6-7, *P=0.0111 
**P=0.0015; ***P=0.0009, Log-rank test). 
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Figure EV5 │ The PDGF pathway is not active in liver metastases.  
A Representative IHC images (left panel) of individual metastases from the PI3K/SHP2 
dual-inhibition group with CD31 staining. Black lines delineate metastases. Scale bar 100 µm. 
Bar graphs (right panel) of microvessel density in livers from mice treated as indicated in the 
adjuvant setting (Fig 5-4D). Measurements obtained with the Aperio Microvessel Analysis 
Algorithm based on CD31 staining. Data shown are means ±STDEV (n=4-7, *P≤0.05, 
**P≤0.01, One-way ANOVA test). 
B Representative images of PDGF Receptor α (Y849)/PDGF Receptor β (Y857) IHC 
staining of livers from mice treated as indicated in the adjuvant setting. Upper panel: liver cells; 
lower panel: metastatic lesions delineated by black lines. Bar graphs (right panel) of 
quantification using the pixel count algorithm performed with Halo software. Scale bar 100 
µm. Data shown are means ±STDEV (n=5-7, *P≤0.05, One-way ANOVA test).  
C Representative 3D culture images of each condition (top panel). Bar graphs of cell 
viability of 3D cultures treated for 5 days as indicated, with medium replacement every 2 days 
(bottom panel). Scale bar 100 µm. Data shown are means ±STDEV (n=4, ****P≤0.0001, One-
way ANOVA test). 
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Supplementary materials and methods 
Compounds 
Sunitinib (Sutent, Pfizer Inc.) was obtained from LC laboratories (Woburn, Mass., USA). 
Sunitinib was prepared as 10 mM stock solutions in DMSO and stored protected from light at 
–20°C. Sunitinib (60 mg/kg) was freshly formulated in methylcellulose/Tween-80 (0.5% / 
0.5%) and administered to mice by oral gavage at 5 ml/kg, once daily. 
3D Cell Culture 
For in vitro drug treatments, 4T1 cells were seeded in DMEM containing 10% FCS and 30% 
Matrigel Growth Factor Reduced (Corning, 356231) at 300 cells per well in 384-well plates in 
quadruplicates. After three days, 3D colonies were treated with DMEM containing 0.5% FCS 
together with CLR457 (1µM), SHP099 (5µM), sunitinib (3.3µM) or combinations. Two days 
later, 50% of the culture medium was exchanged with medium containing drugs at 200% higher 
concentrations. Cells were kept under treatment for a further two days. At treatment day 5, the 
viability of cells was assessed by the CellTiter-Glo 3D Cell Viability Assay (Promega, G9618) 
according to the manufacturer’s instructions. In brief, after removing the culture medium, cells 
were lysed in 25 µl CellTiter-Glo 3D Reagent. After a 30-min incubation at room temperature 
on a horizontal shaker, luminescence was recorded for 0.5 s with an ELISA-reader. 
Immunohistochemistry 
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue 
sections using a Discovery XT (Ventana) fully automated system for anti-CD31 (Spring 
Biosciences). To detect and measure angiogenesis, we performed the Aperio Microvessel 
Analysis Algorithm using CD31 staining. 
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6 | DISCUSSION AND OUTLOOK 
We found that dual-inhibition of PI3K and SHP2 decreases synergistically tumor volumes and 
improves animal survival. Moreover, we demonstrated that the triple combination with the 
addition of VEGFR/PDGFR inhibition further improved animal survival possibly by blocking 
niche-specific signals, which previously rendered metastases resistant to PI3K/SHP2 dual-
inhibition. 
6.1 SHP2 blockade increases PI3K inhibition efficacy 
Several decades of research on signaling pathways have revealed their tremendous importance 
in breast cancer. Among them, the PI3K pathway is hyperactivated in 70% of breast cancer. 
PI3K inhibition shows limited efficacy in clinical settings. Clinical trials were discontinued 
due to high toxicity, or occurrence of resistance. Hence, combinatorial strategies to anticipate 
resistance should be considered. We found that SHP2 inhibition sensitizes breast cancer cells 
to PI3K inhibition, switching from previously insensitive tumors to full regression in most 
cases.  
 Blockade of PI3K/SHP2 in vitro in a panel of breast cancer cell lines reduced cell 
number, with a higher efficacy for the TNBC sub-group. In vivo, we used a TNBC cell line 
where PI3K single inhibition did not affect tumor growth. We observed that PI3K/SHP2 dual-
inhibition decreased tumor volumes, with total tumor regression in 70% of mice. This tumor 
shrinkage was accompanied by an increased tumor cell apoptosis. SHP2 single inhibition 
displayed an intermediate phenotype. Mechanistically, we demonstrated that SHP2 inhibition 
increases p-AKT via upregulation of PDGFRβ, and sensitizes cells to PI3K inhibition.  
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6.2 Effects of PI3K/SHP2 dual-inhibition on metastasis 
Primary tumor resection is a very successful procedure to cure breast cancer patients. However, 
DTC are a major challenge. They remain undetectable and once grown, become difficult 
lesions to cure. In the neo-adjuvant setting, PI3K/SHP2 dual-inhibition enhances survival 
compared to control mice, by reducing lung metastases. Moreover, PI3K/SHP2 dual-inhibition 
in the adjuvant setting led to shrinkage of established lung metastases, and improved animal 
survival. 
6.3 PI3K and SHP2 single blockade: neoadjuvant or adjuvant setting? 
In TNBC, we observed that pan-PI3K inhibition increases lung metastases in the neo-adjuvant 
setting. Equally, we previously published that dual-PI3K/mTOR inhibition in neo-adjuvant 
setting led to larger lung metastases while having no effects on primary tumors (Britschgi, 
Andraos et al. 2012). These observations raise the risk of PI3K blockade in the presence of the 
primary tumor. In contrast, PI3K inhibition in the adjuvant setting improved overall survival 
of mice. Similarly, we found that SHP2 inhibition did not increase animal survival while 
decreasing tumor volumes in the neo-adjuvant setting, but increases animal survival in the 
adjuvant setting. These results highlight the need for careful study design when using such 
inhibitors, and raise the following questions: Does the initial treatment of primary tumors lead 
to more aggressive lung metastases due to higher selection pressure? Are lung metastases in 
adjuvant setting more sensitive to treatments due to unpreceded selection pressure? 
Finally, based on the treatment settings (neo-adjuvant vs. adjuvant), we obtained 
different outcomes that can bias conclusions on drug efficacy, and decisions on pursuing such 
drugs for development and clinical trials. Our findings emphasize the need for careful 
preclinical studies (i.e., that relay not only on primary tumor shrinkage, but also on reduced 
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metastases and enhanced overall survival) before pursuing further development of an 
anticancer drug. 
6.4 From metastatic niche specificities to targeted inhibition design 
We found that mice treated with PI3K/SHP2 dual-inhibition, or with single agents, show 
similar overall survival in the adjuvant setting, arguing that single inhibitions are sufficient. 
We detected lung and liver metastases in mice from single treatment groups, while mice from 
PI3K/SHP2 dual-inhibition group had rare lung metastases, but three times more liver 
metastases. These data suggest a discrepancy between metastatic niches, influencing 
metastases sensitivity to treatment (Psaila and Lyden 2009, Gundem, Van Loo et al. 2015). Our 
data show that lung metastases are sensitive to PI3K/SHP2 dual-inhibition, while liver 
metastases are resistant. 
 We then demonstrated that lung metastases were PDGFRs positive, whereas liver 
metastases are negative. Previous reports have shown that liver metastases are mainly VEGFRs 
dependant (Shaheen, Davis et al. 1999, Chen, Zheng et al. 2017). Thus, we targeted PDGFRs 
and VEGFRs with the clinically approved drug sunitinib, in combination with PI3K/SHP2 
dual-inhibition. We observed a prolonged animal survival, compared to PI3K/SHP2 dual-
inhibition, or sunitinib alone. This raises the possibility that macrometastases display different 
sensitivities based on their niche microenvironment. Additional work is necessary to assess 
further metastatic sites and their response to this triple therapy. 
6.5 SHP2 blockade as a key sensitizer in multiple cancers 
In numerous cancers, the tyrosine phosphatase SHP2 is a key activator of the ERK pathway, 
as well as being a signal enhancer downstream of a large number of RTKs. Recently, SHP2 
blockade has been shown to sensitize cells to ALK inhibition in NSCLC, as well as to MEK 
inhibition in KRAS-mutant background (Dardaei, Wang et al. 2018, Fedele, Ran et al. 2018, 
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Ruess, Heynen et al. 2018, Ahmed, Adamopoulos et al. 2019). Our findings show that SHP2 
inhibition further blocks primary tumor growth and metastasis progression in the context of 
PI3K inhibition. 
 Taken together, our results suggest a fundamental property of SHP2 blockade, 
increasing sensitivity of resistant or non-sensitive cancer cells to PI3K inhibition. Knowing 
that SHP2 promotes self-renewal capacity, breast cancer maintenance, invasion and 
progression to metastasis, dual-inhibition of SHP2 and potent targets in several cancers could 
open new therapeutic strategies.  
6.6 Concluding remarks and future directions 
Unravelling mechanisms of resistance to PI3K inhibitors remains a major clinical challenge. 
In most cases, compensatory signaling initiated by RTKs short circuit the initial inhibition. 
SHP2 is a signal enhancer downstream of RTKs. Recent studies have led to the development 
of SHP2 selective inhibitors, which facilitated the study of the oncogenic properties of SHP2, 
and provided further mechanistic insights.  
In TNBC, SHP2 blockade sensitizes cells to PI3K inhibition. Dual-inhibition decreased 
tumor volumes synergistically, as well as lung metastases in a PDGFRβ dependant manner, and 
increased animal survival. Further analysis revealed that liver metastases resisted such 
combination, most likely via activation of VEGFR. These findings encourage the development 
of new combination strategies to tackle metastatic breast cancers. 
These discoveries raise further questions: 
i. The observation that SHP2 inhibition sensitizes TNBC cells to PI3K inhibition raises 
the question whether this is also the case in other breast cancer subtypes (e.g., ER+, 
HER2) and malignancies. If so, what are the underlying molecular mechanisms? 
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ii. Treatments of mammary cancer cell lines with the SHP2 inhibitor resulted in resistance 
both in vitro and in vivo. What are the mechanisms of resistance to SHP2 inhibition? 
iii. We exclusively focused on the cell-autonomous effects of the PI3K/SHP2 dual-
inhibition. Does PI3K/SHP2 dual-inhibition also enhances survival by non-cell 
autonomous mechanisms? 
iv. Inhibition of SHP2/PI3K/PDGFR/VEGFR enhances overall survival of mice compared 
to single or dual combination but did not result in cure of mice. What are the 
mechanisms of resistance to this combination therapy? 
 
Answering such questions is warranted, eagerly awaited, and further studies are being 
conducted in our laboratory to address them. 
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9 | APPENDICES 
9.1 Abbreviations 
ABL1 Abelson murine leukemia 
viral oncogene homolog 
1 
AKT Protein kinase B 
ALK Anaplastic lymphoma 
kinase 
AML Acute myeloid leukemia 
BET Bromodomain and extra-
terminal domain 
CDK Cyclin-dependent kinase 
CK Cytokeratin 
CNAs Copy number alterations 
CTC Circulating tumor cells 
Cys Cysteine (C) 
d Days 
DCIS Ductal carcinoma in situ 
DNA Deoxyribonucleic acid 
DTC Disseminated tumor cells 
EEC Endometrioid 
endometrial cancers 
EGF Epidermal growth factor 
EGFR Epidermal growth factor 
receptor 
EMT Epithelial-to-
mesenchymal transition 
ER Estrogen receptor 
ERK Extracellular signal-
related kinase 
ESCC Esophageal squamous 
cell cancer 
FACS Fluorescence-activated 
cell sorting 
FAK Focal adhesion kinase 
FDA Food and drug 
administration 
FGFR1 Fibroblast growth factor 
receptor 1 
FIH First in human 
 
 
 
 
FOXO 
 
 
 
 
Forkhead transcription 
factors of the O subgroup 
GAB1 GRB2-associated-binding 
protein 1 
GAB2 GRB2-associated-binding 
protein 2 
GBM Glioblastoma 
GOF Gain-of-function 
GPCR G-protein-coupled 
receptors 
GRB2 Growth factor receptor-
bound protein 2 
h Hour 
HER2 Human epidermal growth 
factor receptor 2 
HGFR Hepatocyte growth factor 
receptor (also called c-
Met) 
HNSCC Head-and-neck squamous 
cell cancer 
HR Hormone receptors 
HSP90 Heat shock protein 90 
hVPS34 Human vacuolar protein 
sorting 34 
IGF-I Insulin-like growth factor 
I 
IGFR1 Insulin like growth factor 
receptor 1 
INSR Insulin receptor 
IRS-1 Insulin receptor substrate 
1 
JAK Janus kinase 
JMML Juvenile myelomonocytic 
leukemias 
KRAS Kirsten rat sarcoma virus 
LEOPARD Multiple lentigines, 
electrocardiographic 
abnormalities, ocular 
hypertelorism, pulmonary 
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stenosis, abnormal 
genitalia, retardation of 
growth, and sensorineural 
deafness 
LOF Loss-of-function 
LS LEOPARD syndrome 
MAPK Mitogen-activated protein 
kinase 
MEK Mitogen-activated protein 
kinase kinase 
METABRIC Molecular Taxonomy of 
Breast Cancer 
International Consortium 
MMP Matrix 
metalloproteinases 
mTORC1 Mammalian target of 
rapamycin complex 1 
mTORC2 Mammalian target of 
rapamycin complex 2  
NRTK Non-receptor tyrosine 
kinase 
NS Noonan syndrome 
NSCLC Non-small-cell lung 
cancer 
NS-LM Noonan syndrome with 
multiple lentigines 
PAR1 Prader-Willi/Angelman 
region-1 
PARP Poly ADP ribose 
polymerase 
pCR Pathological complete 
response 
PDGFR Platelet-derived growth 
factor receptor 
PDGFRβ Platelet-derived growth 
factor receptor beta 
PDK1 Phosphoinositide-
dependent kinase 1 
PD-L1 Programmed death ligand 
1  
PDX Patient-derived xenograft 
PI3K Phosphoinositol 3-kinase 
PI3Ki PI3K inhibition 
PI-4-P Phosphatidylinositol-4-
phosphate 
PIP2 Phosphatidylinositol 4,5-
bisphosphate 
PIP3 Phosphatidylinositol 
(3,4,5)-trisphosphate 
P-loop Phosphate-binding loop 
PR Progesterone receptor 
PTEN Phosphatase and tensin 
homolog 
PTK Protein tyrosine kinase 
PTP Protein tyrosine 
phosphatase 
PTPN11 Protein tyrosine 
phosphatase non-receptor 
type 11 
RAF Rapidly accelerated 
fibrosarcoma 
RAS Rat sarcoma 
RCC Renal cell carcinoma 
RTK Receptor tyrosine kinase 
S6K p70 ribosomal protein S6 
kinase 
S6K1 p70 ribosomal protein S6 
kinase 1 
Ser Serine (S) 
SERD Selective estrogen 
receptor downregulator 
SERM Selective estrogen 
receptor modulator 
SFK Src family kinase 
SH2 SRC homology 2 
SHIP-1 SH-2 containing inositol 
5' polyphosphatase 1 
SHP2 SRC-homology 2 
domain-containing 
phosphatase 
SHP2i SHP2 inhibition 
STAT Signal transducer and 
activator of transcription 
TGF-β Transforming growth 
factor-β 
Thr Threonine (T) 
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TKI Tyrosine kinase inhibitor 
TNBC Triple negative breast 
cancer 
TSC Tuberous sclerosis 
complex 
Tyr Tyrosine (Y) 
VEGF Vascular endothelial 
growth factor 
VEGFR Vascular endothelial 
growth factor receptor 
WHO World Health 
Organization 
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9.2 List of figures and tables 
Introduction 
Figure 3-1│ Breast cancer linear progression model  
Figure 3-2│ Metastatic progression 
Figure 3-3│ Schematic of substrate phosphorylation by PTKs and PTPs 
Figure 3-4│ The classical PTPs family 
Figure 3-5│ Catalytic mechanism of cysteine-based PTPs 
Figure 3-6│ Schematic representation of the protein tyrosine phosphatase 
SHP2 
Figure 3-7│ Schematic of the mechanism of SHP2 activation 
Figure 3-8│ SHP2 mutations result in human diseases 
Figure 3-9│ Schematic overview of class I PI3K catalytic and regulatory 
subunits 
Figure 3-10│ Schematic of the activation mechanism of class IA PI3Ks 
Table 3-1 │ Treatment recommendations for luminal breast cancers 
Table 3-2 │ Treatment recommendations for HER2+ breast cancers 
Table 3-3 │ Treatment recommendations for TNBC breast cancers 
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Results 
Figure 5-1│ PI3K/SHP2 dual-inhibition decreases cell number, reduces 
primary tumor growth and increases overall survival in TNBC 
models. 
Figure 5-2│ SHP2 inhibition sensitizes cells to PI3K inhibition. 
Figure 5-3│ SHP2 inhibition enhances PDGFRα,β signaling. 
Figure 5-4│ Single PI3K or SHP2 inhibition or dual PI3K/SHP2 inhibition 
decrease lung metastases in the adjuvant setting. 
Figure 5-5│ A triple treatment with PI3K, SHP2 and VEGFR/PDGFR 
inhibitors further improves overall survival. 
Figure EV1│ SHP2 single inhibition enhances apoptosis and PI3K/SHP2 
dual-inhibition prolongs overall survival of TNBC-tumor-
bearing mice. 
Figure EV2│ Single inhibition of PI3K or SHP2 in vivo blocks activation of 
the PI3K and the MAPK pathways, respectively, and 
transcriptomic changes are wider following PI3K/SHP2 dual-
inhibition than single inhibitions. 
Figure EV3│ Increased tyrosyl-phosphorylation of several RTKs upon SHP2 
inhibition without effects on the transcriptome of the PDGF-
related gene family. 
Figure EV4│ PI3K/SHP2 dual-inhibition in the adjuvant setting prolongs 
overall survival. 
Figure EV5│ The PDGF pathway is not active in liver metastases.  
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